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Q U I L L  O N  S C A L P E L  This section
provides a medium through which Canadian 
surgeons can declare themselves, briefly and in­
formally, on the day-to-day affairs of surgery.
TREATMENT OF CARCINOMA OF THE THYROID GLAND
It is time that surgeons faced the facts 
concerning thyroid carcinoma. Total thy­
roidectomy is recommended in current 
textbooks and training programs as the 
treatment of choice for papillary or folli­
cular cancers of the thyroid and some even 
recommend radical neck dissection if any 
local lymph-node spread is present. Advo­
cates of total thyroidectomy seem undeterred 
by the lack of evidence that the extent of 
surgical resection influences the outcome. 
Careful assessment of the available evidence 
is required rather than opinions based on 
traditional concepts.
Black, YaDeau and Wollner1 reviewed 
418 cases of papillary carcinoma of the 
thyroid in patients followed-up over a 30- 
year period. The 10-year survival rates were 
84 and 90% for patients with lesions greater 
and smaller than 1.5 cm in diameter, re­
spectively, regardless of involvement of 
lymph nodes. The operations performed 
ranged from a subtotal lobectomy to a total 
thyroidectomy. Crile2 followed 107 conse­
cutive patients with papillary cancer of the 
thyroid for a median period of 11 years. 
There were 10 deaths, all within 5 years of 
the initial operation. The surgical procedure 
varied but most patients had a lobectomy. 
Medina and Elliott3 reported 130 cases 
of thyroid cancer treated by operations 
ranging from subtotal lobectomy to total 
thyroidectomy with neck dissection, in ap­
proximately equal numbers, by 24 different 
surgeons. The survival could be related only 
to the age of the patient at diagnosis and 
the histologic type of the tumour. Complica­
tions were related to the magnitude of the 
operation, as would be expected. The 10- 
year survival in cases of papillary or folli­
cular lesions was similar to that reported by 
others.1' 2> 4 No reports in the literature
suggest that radical local treatment for papil­
lary or follicular lesions influences the prog­
nosis, which is relatively good in any case. 
Although medullary carcinoma of the thy­
roid exhibits different behaviour with more 
rapid progression, evidence that the extent 
of resection alters the outcome is also 
lacking.5
The presence of multiple foci of cancer 
in the thyroid gland is often cited as an 
argument for radical local treatment. No­
body would dispute that multiple foci of 
papillary cancer often can be demonstrated 
histologically. The reported rate of multi­
focal malignant lesions ranges from 30% 6 to 
87.5% 7 and perhaps this figure would be 
increased to 100% if the histologic search 
were intensive enough. One must, however, 
consider performance. It is rare for overt 
carcinoma to develop in a residual thyroid 
lobe.6 What, then, is the natural history 
of these histologic foci of cancer stressed so 
greatly by some surgeons? What of the rate 
of histologically proven carcinoma in multi­
nodular goitres that varies from 4 to 15% 
in different series?8' 11 It is estimated that 
thyroid nodules develop in approximately 
5% of the adult population.12- 13 Accord­
ing to Statistics Canada the annual death 
rate from cancer of the thyroid between 
1950 and 1973 has remained fairly constant 
at around 6/1 million population.14’ 15 
Even if one accepted the lowest figures for 
reported cases of nodular goitres and malig­
nant lesions one would have to deduce that 
many people harbouring carcinoma in their 
thyroid glands live a normal life span with­
out overt evidence of the disease.
There are only two possible explanations 
for these facts. First, in histologic appear­
ance, a malignant tumour in many thyroid 
specimens may be a normal variant, which
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is erroneously labelled “cancer” by the 
pathologist. Second, differentiated carci­
noma of the thyroid may indeed be common, 
but if so, in most cases it must be confined 
by some unknown mechanism to a strictly 
localized microscopic disease. Whichever 
explanation proves to be true, one must 
conclude that radical operative procedures 
on the thyroid gland are irrelevant. Eventu­
ally immunologists may give us a better 
understanding of these facts but in the 
meantime the facts cannot be ignored.
It has also been argued that, for papillary 
and follicular tumours, once surgical treat­
ment is complete, an ablative dose of iodine- 
131 (131I) should be given to eliminate any 
residual thyroid tissue in the neck.16 This 
is indeed aggressive therapy for such a dis­
ease. What potential benefit to the patient 
is evidenced by such treatment in exchange 
for its discomforts and hazards?
At the opposite end of this histologic 
spectrum, anaplastic thyroid tumours pre­
sent a dismal prognosis. No form of therapy 
appears to influence the disastrous course 
except for short-term palliation. Why, then, 
do many surgeons recommend aggressive 
surgical and radiation therapy?
The message is clear. Papillary or folli­
cular carcinoma of the thyroid should be 
locally excised. In most cases this means a 
subtotal or total lobectomy depending on 
the size of the tumour in relation to the 
size of the thyroid lobe: the remainder of 
the gland should be left alone if it is normal 
to palpation. Lymph nodes should be re­
moved singly or in groups only when they 
contain tumour. The theoretical rationale 
for the use of thyroxine therapy is reason­
able, though again it remains to be proved 
that thyroxine reduces the rate of clinical 
recurrence. Ablative 131I therapy should 
be used only in patients with overt evidence 
of widespread disease. For anaplastic tu­
mours therapy should be designed to offer 
meaningful palliation if and when possible.
The concept that the outcome for a pa­
tient with cancer is largely dependent on 
the extent of the surgeon’s intervention is 
indeed attractive as a raison d’etre for sur­
gical intervention. The evidence, however,
suggests otherwise and any surgeon perform­
ing radical procedures for carcinoma of the 
thyroid gland must ask himself what he is 
attempting to achieve in the light of the 
natural history of the disease.
C h a r l e s  J. W r ig h t , MB, FRCS[C], FRCS 
(Eng), FRCS(Edin)
Department of surgery,
University Hospital,
Saskatoon, SK
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PELVIC EXENTERATION FOR 
CARCINOMA OF THE RECTUM
The overall rate of cure for carcinoma of 
the rectum is in excess of 50% . Pelvic 
recurrence is, however, a major technical 
problem. Several techniques have been 
tried to avoid suture-line recurrence after 
low anastomoses. These have included the 
“no touch” technique, use of iodized cat­
gut, and rectal irrigation using water or 
chemical agents. In addition, preoperative 
radiation prior to abdominoperineal resec­
tion has been used, and pelvic exenteration 
has been effective in certain selected cases.
Cohen of the Massachusetts General 
Hospital recently reported (Abdominal Sur­
gery 18: 25, 1976) his experience with a 
49-year-old Negro woman admitted to hos­
pital initially with vaginal bleeding. On 
palpation, a mass was present at the apex 
of the vaginal cuff, contiguous with a large 
rectal mass and the base of the bladder. A t 
operation an ulcerating lesion measuring 
4 x 6  cm was found 7 cm from the anal 
verge. A total pelvic exenteration with sig­
moid colostomy and ureteroileal conduit 
was carried out. A flap of greater omentum 
was used to reconstruct the pelvic floor.
Cohen points out that in patients who 
have rectal cancers with extensive lateral 
or posterior transmural invasion there is 
high risk of local recurrence. As many as 
50% of pelvic recurrences involve struc­
tures anterior to the rectum, including the 
posterior vaginal wall, the cervix, uterus, 
bladder, prostate and seminal vesicles. 
When used for primary treatment of rectal 
cancers, cure rates with pelvic exenteration 
have been about one in three. However, 
pelvic exenteration is not an effective pro­
cedure to treat recurrences after abdomino­
perineal resection.
THE C A N A D IA N  JO U R N A L OF SU R G E R Y
REVIEW  A R TIC LE
GASTROINTESTINAL HORMONES*
STEPHEN N. SULLIVAN, M D f
The availability of pure intestinal hormones and 
the development of radioimmunoassays for their 
measurement has expedited research into many 
aspects of gastrointestinal endocrinology. A 
complex balance evidently exists between the 
different intestinal hormones and also the rest 
of the endocrine system. Polyendocrinopathies 
have been described, and, so far, two diseases 
due to intestinal hormone excess (Zollinger- 
Ellison syndrome and the syndrome of watery 
diarrhea, hypokalemia and achlorhydria] eluci­
dated. It seems likely that many more gastro­
intestinal endocrine diseases await discovery.
La disponibilite d’hormones intestinales pures et 
la mise au point de methodes radio-immunolo- 
giques pour en faire le dosage ont stimule la 
recherche dans plusieurs champs de I'endocri- 
nologie gastro-intestinale. Un equilibre complexe 
existe evidemment entre les differentes hor­
mones intestinales tout comme le reste du sys- 
teme endocrinien. Des polyendocrinopathies ont 
ete decrites et jusqu’a maintenant, on a pu 
elucider deux maladies causees par une hyper­
secretion d'hormone intestinale (le syndrome 
de Zollinger-Ellison et le syndrome de diarrhee 
liquide avec hypokaliemie et achlorhydrie). II 
semble probable que plusieurs autres maladies 
endocriniennes gastro-intestinales seront de- 
couvertes.
It is now evident that not only is the gastro­
intestinal (GI) tract a major endocrine or­
gan1 but also that there are complex rela­
tions between intestinal hormones and other 
endocrine organs. Two elaborate reviews on 
the subject have recently become avail­
able,2’ 3 and, in another publication, I pub­
lished a brief summary. 4 The pertinent lite­
rature is made complex by interspecies vari­
ations and by the experimental use of non- 
physiologic doses of impure hormones. In 
this paper I shall try to confine discussion 
to data obtained, where available, from the 
use of relatively pure hormone preparations 
in man.
A p u d  C e l l s
The endocrine polypeptide cells of the
*From the gastrointestinal unit, Victoria Hospital, 
University of Western Ontario, London, ON. 
tPresent address: Liver unit, King’s College Hos­
pital, London, England.
TA B LE  I.— Hormones Produced by Apud Cells
Cell type Hormone produced
G ut polypeptide cells Gastrin, secretin, C C K . 
“ enteroglucagon” , 
G IP, VIP, motilin
Pituitary melanotroph MSH
Pituitary corticotroph ACTH
Parafollicular C cell Calcitonin
Pancreatic p cell Insulin
Pancreatic <X2 cell Glucagon
Pancreatic ai cell 
Adrenal medulla 
Carotid body 
“ Endocrine cells’ ol 
the lung
Gastrin
gut belong to a family of cells to which, 
from their cytochemical and ultrastructural 
characteristics, the acronym Apud (amine 
precursor uptake and decarboxylation) re­
fers. These cells, also found in the pituitary, 
thyroid and adrenal glands, and the pan­
creas and lungs5 (Table I) are believed to be 
of neuroectodermal origin and to migrate 
from the neural crest. 6 The common origin 
of these cells may partially explain both 
the common amino-acid sequences in dif­
ferent hormones and some of the polyen­
docrinopathies —  Wermer’s syndrome (pi­
tuitary adenoma, islet cell tumour, para­
thyroid adenoma or hyperplasia) and Sip­
ple’s syndrome (medullary thyroid carci­
noma, pheochromocytoma, parathyroid ade­
noma or hyperplasia).7, 8 Tumours of this 
cell series have been termed apudomas. 9
The nomenclature for these cells is com­
plicated and is in a state of flux; the trend 
seems to be to name the cells for the hor­
mone they produce.
M o d e  o f  A c t io n  o f  GI
H o r m o n e s
The mechanism of release of G I hor­
mones is not known but evidence points to 
cholinergic and adrenergic pathways. Anti­
cholinergics inhibit the pancreatic secretory 
response to secretin releasers more than the 
response to exogenously administered secre­
tin; 10 topical anesthetics applied to the in­
testinal mucosa reduce the response of the 
pancreas to intestinal stimulants, 11 and
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hexamethonium prevents the release of 
cholecystokinin (CCK).1 - Infusions of phys­
iologic doses of adrenalin are known to re­
lease gastrin,13 an effect that may be in­
hibited by !3 blockade. In the future, 
stimulators and inhibitors of Gl-hormone 
release may be of therapeutic value in the 
management of diseases of Gl-hormone defi­
ciency and excess, which are sure to be 
described.
Gl-hormone receptors have not been de­
scribed but Grossman14 has postulated that 
gastrin, CCK, secretin and glucagon act on 
one receptor with two interacting sites. Gas­
trin and CCK, which share a terminal penta- 
peptide, are thought to act at one site, and 
secretin and glucagon, which also have 
structural similarities, at the other. The re­
sult of a simultaneous action of hormones 
depends on whether it leads to competitive 
or noncompetitive augmentation or inhibi­
tion.
Gastrin and CCK are believed to act on 
the lower esophageal sphincter (LES) and 
small bowel by stimulation of postganglionic 
cholinergic neurons.13 Their action on the 
gallbladder, however, may be through direct 
stimulation of the muscle.16 One intestinal 
hormone, motilin, may act through direct 
release of acetylcholine from nerve end­
ings.17
The histamine HL>-receptor antagonists 
metiamide and cimetidine are universal 
blockers of all gastric secretory stimuli, in­
cluding vagal stimulation, gastrin, choli­
nergic agents, histamine and food,18' 19 and 
it may be that histamine is the final step in 
the mode of action of all gastric stimulants.
Biochemically, the mode of action of in­
testinal hormones is still speculative. Cyclic
adenosine monophosphate (AMP) is a fac­
tor in intestinal secretion29 and prostaglan­
din activity,21 and, while it is probably 
true that cyclic nucleotides mediate some 
of the action of intestinal polypeptide hor­
mones, there is still not sufficient proof 
to implicate them.
Proven GI H ormones
Gastrin
Gastrin, the most extensively studied of 
the GI hormones, exists in several molecular 
forms (Table II22‘2i’); however, the nomen­
clature for the different forms has not been 
standardized and each investigative group 
uses its own terms.
Three gastrin species have, by means of 
gel filtration, been reliably identified —  gas­
trin-34, gastrin-17 and gastrin-13 — accord­
ing to the number of amino-acid residues 
they contain.22 The C-terminal amino-acid 
sequences of each molecule are identical 
and each may exist in a sulfated or non- 
sulfated form.
Gastrin-34 corresponds to the “big gas­
trin” of Yalow and Berson.26 It is the 
major circulating form of gastrin in the 
fasting state and its secretion is stimulated 
by feeding; its half-life is reportedly 9 to 
15 minutes.27' 28 Gastrin-17, the heptade- 
capeptide form, is also released by feeding 
and has a serum half-life of 3 to 5 minutes. 
Gastrin-13 is a “minigastrin” with a short 
half-life of 1.8 minutes.25- 29 Gastrin-34 
and lesser amounts of gastrin-17 are the 
major circulating forms in pernicious anemia 
and the Zollinger-Ellison syndrome (ZES).
Three other forms of gastrin have been 
found in the circulation and in tissues. The 
biologically inactive N-terminal tridecapep-
TABLE II.—Species of Gastrin
Investigative group and nomenclature P roperties
W alsh -2 Rehfeld23 Yalow24
Gram  
form ula  
Gregory25 weight
A m in o
acids
Release 
by food
T i
{m in)
mixture of 
large molecules
“Big, big 
gastrin”
— 20 000 ? No 90
Component I — — Similar to 
proinsulin
? ? ?
Gastrin-34 Component II “Big gastrin” “Big gastrin” ~3900 34 Yes 9-15
Gastrin-17 Component III Gastrin “Little gastrin” ~2100 17 Yes 3-5
Gastrin-13 Component IV — “Minigastrin” ~1600 13 ? 1.8
A
4
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tide of gastrin-17 has been identified by 
selective radioimmunoassay in the serum 
of patients with gastrinoma.30 A “big, big 
gastrin” found in the jejunum and serum 
of healthy individuals and in the serum and 
tumour tissue of patients with gastrinoma 
has been isolated by Yalow and others-4’ 31 
from the void volume of Sephadex gel 
filtration columns; serum concentrations are 
not affected by feeding and this form of 
gastrin circulates with a half-life of ap­
proximately 90 minutes. Rehfeld, Stadil and 
Vikelsoe32 and Rehfeld23 have found a 
gastrin designated Component I, that, since 
it elutes just before gastrin-34 on Sephadex 
G50-SF columns, is presumably larger than 
gastrin-34. These workers, however, have 
not been able to identify a homogeneous 
“big, big gastrin” and they suggest that it 
may be a heterogeneous mixture of gastrin 
species of differing sizes.32
Gastrin exists in large quantities in the 
gastric antral G cells and proximal duode­
num and in lesser amounts in the gastric 
cardia, pancreatic islet D or cells, and 
in progressively diminishing amounts along 
the intestinal mucosa.33 The relative amounts 
of the larger molecular species appear to 
increase further down the intestine.
The major stimuli for gastrin release are 
those associated with eating —  vagal stimu­
lation, antral distension and the contact of 
protein products with the gastric antrum. 
Besides these physiologic stimuli several 
pharmacologic stimuli are also known to 
release gastrin, including calcium (intrave­
nous or oral),34 epinephrine13 and bile 
salts.33 The release of gastrin by epine­
phrine has been suggested as the explana­
tion for elevated gastrin levels in pheochro- 
mocytoma36 and for the release of gastrin 
during insulin hypoglycemia after complete 
vagotomy.37- 38 These effects may be pre­
vented by either a or (3 blockade.36' 39
Inhibition of gastrin release follows acidifi­
cation of the gastric antrum to a pH below 
3. (Alkalinization of the antrum may en­
hance gastrin release by preventing feed­
back inhibition by acid, and the loss of 
antral acidification in pernicious anemia 
and atrophic gastritis leads to sustained gas­
trin release and high serum levels; elevated 
gast.xt levels have also been reported in 
rheumatoid arthritis40 but the reason for
this elevation is not known.) Glucagon41’ 42 
and secretin,43’ 44 which normally decrease 
gastrin release (and inhibit the action of gas­
trin), cause a paradoxical increase in patients 
with ZES. This has been suggested as a 
diagnostic test for this syndrome, as has 
calcium infusion.45
Recently, serum concentrations of cal­
citonin, the hypocalcemic hormone produced 
by the parafollicular C cells of the thyroid, 
have been shown to be elevated in ZES. 
Conversely, medullary carcinoma of the 
thyroid, a calcitonin-producing tumour, is 
associated with low serum-gastrin concentra­
tions.46 These data suggest that gastrin 
stimulates calcitonin release and that cal­
citonin, in turn, inhibits gastrin release. As 
well as inhibiting gastrin release in large 
doses, calcitonin also inhibits the acid secre­
tory effects of gastrin in smaller doses.47
Anticholinergics, such as atropine, will 
block the vagal release of gastrin but will 
not prevent gastrin release during feeding. 
Anticholinergics will also impair the gastric 
secretory response to gastrin.
The major physiologic effects of gastrin 
appear to be related to gastric secretion of 
acid, pepsin and intrinsic factor. Gastrin 
may also be a major determinant of pres­
sure in the normal LES,48 though there is 
controversy on this point.49’ 50 Other secre­
tory and motor effects have been observed 
on the pancreas, biliary tree and intestine 
(Table I II51' 53). Gastrin also has trophic 
effects on the stomach, duodenum and pan­
creas54' 56 and stimulates the secretion of 
secretin,57 insulin58 and calcitonin.59 At 
present, these actions appear to have minor 
physiologic significance.
The sites of gastrin degradation have not
TABLE III.—Actions of Gastrin
Secretory
Acid, pepsin and intrinsic-factor secretion 
Pancreatic enzyme production 
Increase in bile flow
Secretin stimulation, insulin and calcitonin release 
Decrease in intestinal salt and water absorption61 
Motor
Increase in LES pressure 
Increase in gastric motility
Relaxation of ileocecal valve and sphincter of 
Oddi62
Weak intestinal motility stimulant63 
Miscellaneous
Trophic effects on stomach, duodenum and pan­
creas
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been fully defined, but evidence suggests 
that the small bowel,60 gastric fundus61 and 
kidney62"64 are important in gastrin clear­
ance. These organs59' 60' 61' 63 appear to 
extract gastrin during stimulated gastrin re­
lease but not under basal conditions. Neph­
rectomy prolongs the half-life of gastrin,62 
and patients with acute63 and chronic 
renal failure66 have elevated basal gastrin 
levels. In our laboratory prolonged cir­
culation of gastrin has been demonstrated 
in uremic patients following a test meal.67 
The loss of gastrin-degrading function in ure­
mia may not be related to loss of glomerular 
filtration rate, but to the loss of normal func­
tioning renal mass.68 The liver appears not 
to be a major degrader of gastrin and, in 
contrast to the rapid inactivation of penta- 
gastrin by the liver, exogenous and endoge­
nous gastrin are not appreciably affected by 
passage through the portal circulation.69' 70
Cholecystokinin
Cholecystokinin is a 33-amino-acid poly­
peptide, released from the mucosa of the 
upper small bowel by the hydrolyzed prod­
ucts of fat and protein digestion, by high 
concentrations of acid,71 and possibly by 
magnesium sulfate.72 The five C-terminal 
amino-acid residues are similar to gastrins. 
This structural similarity to gastrin may ac­
count for some of the effects of CCK. In 
the presence of gastrin, CCK may act as a 
competitive antagonist of gastrin but in its 
absence acts as a partial agonist of some 
of the effects of gastrin.
The major effects of CCK (Table IV 73" 
75) relate to stimulation of pancreatic en­
zyme secretion and contraction of the gall­
bladder. It also has motor effects on the 
sphincter of Oddi, small intestine,72 
colon67 and pyloric sphincter.77 Impure 
preparations may stimulate pancreatic glu-
TABLE IV.—Actions of Cholecystokinin
Pancreatic enzyme secretion 
Gallbladder contraction 
Relaxation of sphincter of Oddi 
Intestinal and colonic motility 
Increase in pyloric sphincter pressure 
Competitive inhibition of gastrin 
Stimulation of gastric secretion in absence of gastrin 
Release of alkaline phosphatase from small 
intestine73
Release o f intestinal disaccharidases74 
Small intestinal secretion76
cagon and insulin secretion78 but highly 
purified CCK has no effect.2
Research into the effects of CCK has 
been hampered by the lack of a reliable 
radioimmunoassay for the hormone and of 
readily obtainable pure hormone. Commer­
cially available CCK preparations may con­
tain only 20% by weight of CCK. Radio­
immunoassays for CCK have been re­
ported79- 80 but these have not yet been 
proved reliable. Thus, biologic assays have 
been used for CCK and, experimentally, the 
synthetic octapeptide of CCK or cerulein 
(a decapeptide structurally similar to CCK 
and obtained from the skin of the Australian 
tree frog Hyla caerulea) are frequently used.
Secretin
This topic was reviewed in 1972 by 
Hubei.81
Secretin is a 27-amino-acid polypeptide. 
Fourteen of the amino acids occupy the 
same position in secretin as in glucagon. 
Secretin is produced by the small granular S 
cells in the transitional zone between the 
crypts and the villi of the upper small 
bowel.82
The chief stimulus for release of secretin 
is duodenal acidification. The threshold for 
release is approximately pH 4.5 and the 
amount of secretin released is believed to 
be related to the rate of acid input and, 
hence, the length of bowel acidified. (How­
ever, the physiologic role of acid alone 
in stimulating secretin release has been ques­
tioned,83 since the pH necessary for such 
release may not be present in the postcibal 
period.) Secretin may also be released by 
protein,84 gastrin and bile salts.80 The ques­
tion of whether secretin is released by vagal 
stimulation or the products of fat diges­
tion has not been resolved.
The main physiologic effect of secretin 
is stimulation of pancreatic volume and elec­
trolyte secretion. Besides its effects on the 
pancreas, secretin has positive and negative 
secretory and motor effects elsewhere in the 
GI tract (Table V 73"76- 86"90). n  decreases 
the release of gastrin91 and acts as a non­
competitive inhibitor of gastrin on the gas­
tric parietal cells and the LES.92
Secretin may be a factor in the patho­
genesis of peptic ulcer. The positive ino­
tropic effects of secretin on the pyloric
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sphincter93 may be important in preventing 
duodenogastric reflux, which is thought to 
be of etiologic significance in gastric ulcer.94 
Impaired secretin release has been demon­
strated in patients with duodenal ulcers95 
while exogenous secretin is a strong inhi­
bitor of meal or pentagastrin-induced gas­
tric secretions in such patients.96
Enteroglucagon
A substance with glucagon-like immuno- 
reactivity has been identified in the intes­
tinal mucosal L cell, gastric mucosal A cell 
and in plasma.97, 98 There are species vari­
ations in mucosal location, and its exact 
location in man has not been identified. It 
appears, however, that the largest quantities 
are found in the ileum.99 It can be distin­
guished from pancreatic glucagon by selec­
tive immunoassay and by its molecular 
weight (approximately 7000), which is twice 
that of a major pancreatic glucagon frac­
tion.100 Like gastrin, it may exist in small 
and large molecular forms.101
Unlike pancreatic glucagon, it is released 
into the circulation by glucose98 and long- 
chain triglycerides.102 After a partial gas­
trectomy103 or vagotomy and pyloro­
plasty104 (particularly in patients with a 
“dumping syndrome”) and in patients with 
essential alimentary hypoglycemia (vide 
infra) large amounts of enteroglucagon may 
be liberated into the circulation following 
the ingestion of carbohydrates.
Enteroglucagon appears to be devoid of 
glycogenolytic activity and it has been hypo­
thesized that it may competitively inhibit 
the hepatic actions of pancreatic gluca-
TABLE V.— A ctions of Secretin
Secretory
Pancreatic volume and bicarbonate secretion 
Increase in bile flow 
Pepsin secretion 
Brunner’s-gland secretion
Increase in jejunal secretion and decrease in ab­
sorption75, 86
Decrease of gastric secretion 
Release of insulin87 
Decrease in stimulation of gastrin 
Release of alkaline phosphatase from brush 
border73
Release of intestinal disaccharidases74 
Elevation of serum calcium concentration88 
Motor
Decrease in LES pressure
Decrease in gastric motility89
Decrease in small bowel9 0  and colonic motility76
Increase in pyloric sphincter pressure
gon.105 Whether it stimulates insulin re­
lease has not been resolved, but available 
evidence suggests that it does not, since 
galactose, fructose, xylose, mannose and 
3-0-methyl glucose all raise serum levels of 
enteroglucagon without affecting insulin 
levels.106
An enteroglucagon-producing renal tu­
mour, causing severe small and large bowel 
stasis with marked hypertrophy of the small 
intestinal villi, has been reported. Following 
removal of the tumour all abnormalities re­
mitted.107, 108
The physiologic role of enteroglucagon is 
unknown. It has been suggested that its 
release from the lower small intestine may 
“act to produce a slowing of further food 
transport and also to enhance long-term 
growth of the absorptive intestinal mu­
cosa”.109
Gastric Inhibitory Polypeptide
Gastric inhibitory polypeptide (GIP) is a 
43-amino-acid polypeptide, with structural 
similarities to porcine secretin and glucagon, 
which has been isolated by Brown and 
Dry burgh110 from an impure preparation 
of porcine CCK. It has been identified by 
radioimmunoassay in the serum of m an111 
and is believed to be released from the D x 
cells of the upper small bowel mucosa112 
by food, particularly glucose and fat.113
In microgram doses it inhibits both an­
tral and fundic motor activity and the gas­
tric acid and pepsin secretory response to 
pentagastrin, histamine and insulin hypo­
glycemia.114 GIP is believed to stimulate 
intestinal secretion,115 and one case of pan­
creatic cholera has been attributed to a 
GIP-producing tumour.116 No effect has 
been observed on the gallbladder or exo­
crine pancreas, but recently intravenous in­
fusion of GIP has been demonstrated to 
potentiate the insulin secretory response to 
intravenous glucose.117
The physiologic implications of GIP will 
be discussed under the section on enterogas- 
trone.
Vasoactive Intestinal Peptide
Vasoactive intestinal peptide (VIP) is a 
28-amino-acid polypeptide with structural 
similarities to glucagon, secretin and 
GIP.118 These structural similarities are 
related to its different actions, which in-
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elude stimulation of pancreatic and intes­
tinal secretion,115 induction of hypergly­
cemia119 and inhibition of gastric acid and 
pepsin secretion. It also has vasodilatory 
activity, from which it derives its name,120 
and inhibitory effects on tracheal, gastric 
and gallbladder smooth muscle.
VIP was originally isolated from the up­
per porcine small intestine but has now 
been demonstrated by radioimmunoassay to 
be distributed throughout the primate gut 
in quantities exceeding that of gastrin, secre­
tin, or CCK.121
The physiologic function of VIP is 
presently unknown but, pathologically, it 
has been shown to be associated with the 
syndrome of watery diarrhea, hypokalemia 
and achlorhydria (WDHA) secondary to 
pancreatic or retroperitoneal neoplasms.122-
123
Motilin
Motilin is a 22-amino-acid polypeptide 
that has been isolated from the mucosa of 
the upper 1 m of the porcine small intes­
tine.124- 125 Its structure is distinct from 
that of the other gastrointestinal polypep­
tides.126 Intravenous injection of nano­
gram doses in dogs leads to increased gas­
tric antral and fundal motor activity and 
increased pepsin output with no increase in 
acid secretion.124 In the dog the stimulus 
for its release is believed to be increased 
alkalinity of the duodenum.127 However, 
in man, two recent reports suggested that 
motilin may be released by duodenal acidifi­
cation128 and in fact delay gastric empty­
ing. 129 The mode of action of motilin may 
lie in release of acetylcholine from nerve 
endings.1 ' The physiologic role of motilin 
is presently unknown but it may function 
as a regulator of constant gastric input into 
the duodenum.
Prostaglandins
Prostaglandins are oxygenated cyclic C20 
fatty acids and, as such, are not polypeptide
intestinal hormones. They are mentioned 
here only because under certain pathologic 
and pharmacologic circumstances they 
exert a hormonal effect on the GI tract.
The effects of prostaglandins on the gut 
have been reviewed by Waller,130 Bennett 
and Fleschler131 and Wilson.132 There is 
evidence both for the synthesis, release 
and degradation of prostaglandins in the 
gut and for action of ingested or injected 
prostaglandins on the gut. However, pros­
taglandins have not been demonstrated to 
act as GI hormones under normal physio­
logic conditions. Prostaglandins E2 and F2 a 
are the major extractable forms found in 
the GI mucosa and pancreas of man. Their 
function is unknown, but it is suggested that 
they may act as local mediators of secretion 
and motility. The mode of action of prosta­
glandins is also unknown, but there is sub­
stantial evidence to suggest that they act 
through stimulation or inhibition of adenyl 
cyclase and hence, the “second messenger” 
cyclic AMP.21
The diarrhea that may be associated with 
thyrojd medullary carcinoma, ganglioneu­
romas, pheochromocytomas, islet cell tu­
mours and ileal carcinoids may result from 
prostaglandin production and release by 
these tumours.133- 134
Prostaglandins E 1; E2 and Ax have gas­
tric antisecretory effects during basal and 
stimulated gastric acid secretion.135' 138 
Prostaglandin analogues that are potent and 
orally active with few side effects may be of 
therapeutic benefit in gastric hypersecretory 
states139 and it is possible that the ulcero­
genic effects of acetylsalicylic acid and indo- 
methacin may be related to their inhibitory 
action on prostaglandin synthesis.
Some of the other effects of exogenously 
administered prostaglandins in man are 
listed in Table V I.140 
Hypothetical GI Hormones 
The existence of two hormones, “incre­
tin” and “enterogastrone”, has been postu-
P rostaglandins in M anTABLE VI.—E ffects of
Prostaglandin Fia. Prostaglandin E \
Increase in LES pressure140 Relaxation of LES
Contraction of circular and longitudinal Contraction of longitudinal and relaxation
smooth muscle of circular smooth muscle
stimulation of intestinal secretions Stimulation of intestinal secretion
Inhibition of basal and stimulation of acid secretion
r
\
4
1
4
V
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lated to explain the observed physiologic 
effects that follow eating, including aug­
mented insulin secretion and feedback in­
hibition of gastric secretion and motility.
Incretin
This topic has been well reviewed.2’ 141' 
144 It is established that, for a given eleva­
tion in blood sugar concentration, oral ad­
ministration of glucose leads to a higher 
and more sustained insulin response than 
intravenous administration.145’ 146 The 
same is true for amino acids.147 It is pre­
sumed that the augmented insulin response 
is due to hormonally stimulated insulin re­
lease. Secretin,87 impure CCK, gastrin,58 
glucagon, G1P,117 VIP and duodenal ex­
tracts (insulin-releasing polypeptide)148 are 
all capable of stimulating insulin secretion. 
It is not known which (if any) of the GI 
hormones is a true physiologic intestinal 
insulin secretogogue. Several hormones may 
act in concert to produce the observed ef­
fects. Release of these hormones may be 
inducible since carbohydrate restriction will 
blunt the insulin response to an oral glucose 
tolerance test.149 The biguanide, phen- 
formin, may inhibit insulin release after food 
by inhibition of intestinal hormone re­
lease150 as well as by impaired glucose ab­
sorption.151 The clinical ramifications of 
incretin will be discussed further under the 
section on alimentary hypoglycemia.
Enterogastrone
The introduction of fat, acid or hyper­
tonic solutions into the duodenum is known 
to inhibit the gastric secretory response to 
gastrin, pentagastrin, histamine, insulin hy­
poglycemia and a meal. The term “entero­
gastrone” is applied to a hormone that, 
when released from the duodenal mucosa, 
would inhibit gastric secretion. Several pos­
sibilities exist (Table VII), including secre­
tin,90 CCK, GIP and glucagon. Other in­
hibitors of gastric secretion have also been 
described including sialogastrone (isolated 
from saliva152), bulbogastrone (isolated 
from the duodenal bulb152), gastrone B 
(found in human achlorhydric gastric juice 
and identified in the antral mucosa153- 154) 
and urogastrone (isolated from urine). The 
function of these substances is unkown.
Of all the possible enterogastrones, the 
GIP of Brown110 is the most likely can­
didate. It alone (and perhaps VIP) inhibits 
the secretory response to all known gastric 
stimulants as well as inhibiting gastric moti­
lity. Under physiologic circumstances, how­
ever, enterogastrone may comprise several 
hormones acting in concert to produce the 
observed effect of inhibition of gastric secre­
tion and motility.
A natomical Loci of Activity
The multiple and varied effects of the 
intestinal hormones on the stomach and 
pancreas have been extensively investigated 
and described. It is only in recent years 
that more interest has been directed towards 
the LES, pyloric sphincter and large bowel. 
These aspects will be considered more fully.
Lower Esophageal Sphincter
Since the advent of continuous-perfusion 
esophageal manometry,155 the physiologic 
and pharmacologic properties of the LES 
have been more accurately defined.156 The 
chief function of the LES is to maintain a 
pressure barrier between the gastric cardia 
and the body of the esophagus. Positive 
inotropic influences are exerted on the 
sphincter by increased intragastric pressure, 
vagal stimulation, cholinergic drugs, alpha 
adrenergic drugs,157 metoclopramide,158 
prostaglandin Fs*159 and gastrin.160 Gas­
trin is the influence of major pharmacologic
TABLE VII.—Actions of Possible E nterogastrones
Hormone
Variable factor CCK Secretin Glucagon GIP
..........  Fat, acid Acid Hypoglycemia Fat
Acid inhibition response to
..........  + + + +
— — +
Inhibition of gastric motility......................
Inhibition of pepsin......................................
..........  +
..........  +
+ +V
+
+
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(and perhaps physiologic) importance and 
probably acts via stimulation of postgangli­
onic cholinergic neurons. Negative inotropic 
effects are exerted by secretin, 92  gluca­
gon, 1 6 1  CCK , 1 6 2  beta adrenergics, 157
anticholinergics, 1 5 6  prostaglandins E1; E 2 
and A 2 , 1 6 3  smoking1 6 4  and the ingestion 
of fatty food. 1 6 5
Changes in intragastric pH also affect 
LES pressure, but whether these pressure 
changes are secondary to changes in serum 
gastrin levels or not is unclear. Higgs, Smyth 
and Castell1 6 6  have observed pH-dependent 
sphincter-pressure changes without appreci­
able alteration in total serum gastrin as 
measured by radioimmunoassay. However, 
presently available immunoassays are not 
able to distinguish between the different 
gastrin species, so changes in the molar ratio 
of the different molecular species (and 
hence, biologic activity) may occur without 
affecting the total gastrin. This problem re­
mains to be solved.
A number of patients with gastro­
esophageal reflux have a hypotensive LES 
that responds poorly to stimuli (the hypo­
tensive, hyposensitive LES); the presence or 
absence of a hiatal hernia appears to be 
of little importance. 1 6 7  The disorder may 
be a combination of relative hypogastrinemia 
and end-organ resistance to gastrin. Post­
prandial (and possibly fasting) gastrin con­
centrations may be diminished while exo­
genous administration of gastrin causes 
little absolute increase in LES pressure.168’ 
1 6 9  However, the exact physiologic mechan­
ism of gastroesophageal reflux is unknown.
On the other hand, the disorder of 
achalasia is characterized by the presence 
of a hypertensive, hypersensitive LES, 1 7 0  
which may fail to relax on swallowing. In­
hibition of gastrin release via antral acidifi­
cation will decrease the sphincter pres­
sure. 1 7 1  Paradoxically, patients with per­
nicious anemia or ZES, diseases in which 
the serum gastrin values are grossly ele­
vated, have sphincters of different com­
petence. Poor sphincter function is found in 
pernicious anemia172  while patients with 
ZES have excellent sphincter function.173’
174
Stomach
The actions of the polypeptide hormones
on the gastric parietal cell and antral pump 
have been discussed. Gastrin stimulates 
both secretory and motor activity while 
secretin, CCK, glucagon and GIP inhibit 
both actions.
Pyloric Sphincter
The pylorus is a true sphincter and has 
a function in preventing duodenogastric re­
flux. 9 3  Pyloric pressure may be increased 
by intraduodenal instillation of acid, olive 
oil, amino acids, glucose and hypertonic 
solutions. Likewise, exogenous administra­
tion of secretin, and CCK increase pyloric 
sphincter pressure. 77 Gastrin inhibits the 
effects of these hormones. 1 7 5  Smoking will 
also decrease pyloric sphincter pressure. 1 7 6  
Pyloric sphincter incompetence and reflux 
of duodenal contents may influence the 
development of gastric ulcers.
Pancreas
Several reviews of the hormonal control 
of pancreatic function have recently been 
published.71’ 78  The chief hormonal influ­
ences on the pancreas are as follows. Secre­
tin increases the volume of pancreatic secre­
tions and bicarbonate and insulin secretion 
while CCK stimulates pancreatic enzyme 
and glucagon release. Glucagon inhibits 
pancreatic exocrine function by influencing 
enzyme release and synthesis. Insulin, on 
the other hand, appears to have trophic 
effects on the pancreatic acinar cells. The 
physiologic role of the other GI hormones 
on pancreatic function is unknown.
Large Bcrwel
As already mentioned, at least two in­
testinal polypeptides affect the function of 
the colon. Intravenous infusion of CCK1 7 7  
or its endogenous release via oral adminis­
tration of magnesium, 1 7 8  or duodenal in­
fusion of fats and amino acids1 7 9  will 
stimulate sigmoid colonic motility. Infusion 
of secretin will inhibit the motor response 
to CCK . 76  Neither of these hormones is 
believed to act on the rectum. Gastrin is 
not thought to have a motor effect on the 
large bowel.
The implications of the colonic effects of 
GI hormones will be considered in a dis­
cussion of the irritable bowel syndrome.
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GI H orm ones in  D isea se
An excess or deficiency of GI hormones 
will have varied manifestations. Only five 
disorders will be mentioned here: celiac 
disease, peptic ulcer disease, pancreatic 
cholera, alimentary hypoglycemia and the 
irritable bowel syndrome.
Hormone Deficiency
Theoretically, any disorder that damages 
the upper intestinal mucosa could lead to 
secondary deficiency of small bowel hor­
mones. At first glance, celiac disease or 
gluten-induced enteropathy appears to 
be such a disorder. Hypofunction of the 
pancreas1 8 0 '1 8 2  and gallbladder183, 184  
following oral administration of hormone 
releasers has been described in celiac dis­
ease. These physiologic alterations would 
imply deficiency of secretin and CCK; how­
ever, Polak and colleagues1 8 5  have de­
scribed hypertrophy and hyperplasia of the 
intestinal secretin cells in celiac disease, 
suggesting possibly a poor release reaction. 
On the other hand, Low-Beer and asso­
ciates180  have demonstrated abnormally 
high fasting levels of CCK with a slow rise 
to normal levels following feeding in celiac 
disease. These results remain to be con­
firmed and explained.
Secretin deficiency has been proposed as 
an etiologic factor in peptic ulcer disease, 
and a deficiency of enterogastrone may ac­
count for the increased incidence of in­
testinal ulceration in celiac disease. 1 8 7
As techniques improve, true primary and 
secondary deficiencies of GI hormones are 
likely to be described.
Peptic Ulcer Disease
Except for ZES, the role of intestinal 
hormones in peptic ulcer disease has not 
been fully defined. Gastrin may be a factor 
in the gastric hyperacidity observed in duo­
denal and distal gastric ulcers. 1 8 8  Recently, 
McGuigan and Trudeau1 8 9  have demon­
strated that patients with duodenal ulcer 
disease have an increased gastrin response 
to a standard protein meal, increased sen­
sitivity to pentagastrin1 90  and a higher and 
more prolonged gastrin response to insulin 
hypoglycemia. 101  Unlike ZES patients, 
they have neither fasting hypergastrinemia
nor a paradoxical gastrin secretory response 
to glucagon and secretin. The possibility 
that the hypersecretion of duodenal ulcer 
disease results from deficient enterogastrone 
has also been considered1 9 2  and it is of 
interest that Bloom and Ward95  have dem­
onstrated deficient secretin release in a 
small group of duodenal ulcer patients.
It has been postulated that gastric ulcers 
may be due to pyloric sphincter dysfunction 
and duodenogastric regurgitation of bile 
and intestinal juices. 77  Damage to the mu­
cosa would allow back diffusion of hydrogen 
ions into the mucosa, thus explaining the 
hypoacidity frequently noted in these pa­
tients. The hypoacidity, in turn, would en­
hance gastrin release, 1 9 3  which could then 
block the normal pyloric response to CCK 
and secretin. 1 7 5
Peptic ulcer disease also has a strong 
association with chronic renal failure, 1 9 4  
cirrhosis and portosystemic shunting, and 
massive small bowel resection.195, 1 9 6  The 
peptic ulcer disease of chronic renal failure 
may be due to hypergastrinemia66  and gas­
tric acid hypersecretion secondary to im­
paired renal degradation of gastrin. 6 1 ' 64  
There is, however, no direct correlation be­
tween hypergastrinemia and the presence 
or absence of peptic ulcer disease. 6 7  Simi­
larly, the gastric hypersecretion that follows 
massive small bowel resection may be due 
to hypergastrinemia secondary to impaired 
extraction of endogenous gastrin by the small 
bowel, 60  or to enhanced secretion of gastrin 
secondary to a deficiency of small bowel 
gastrin secretory inhibitory substances. 1 9 7  
Gastrin is not affected by passage through 
the portal circulation7 0  and hypergastrine­
mia has not been documented in cirrhosis 
or following portosystemic shunting. The 
gastric hypersecretion that occurs in these 
situations may be secondary to increased 
sensitivity of the gastric parietal cell mass 
to normal levels of circulating gastrin. 1 9 8
Surgical modifications of the upper gas­
trointestinal tract will affect gastrin levels. 
After vagotomy (truncal, selective or highly 
selective) basal and postcibal gastrin levels 
are elevated. 3 7  Pyloroplasty will partially 
attenuate the postcibal response. 1 9 9  Similar 
postcibal elevations have been observed in 
patients given atropine. 2 0 0  It has been stated 
that complete vagotomy will prevent the
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gastrin secretory response to insulin hypo­
glycemia201' 202 but the consensus of the 
available literature is that this statement is 
incorrect.37 Gastrin release during insulin 
hypoglycemia persists following complete 
vagotomy.37- 100 Continued gastrin secre­
tion may be related to gastrin release via 
adrenergic influences.13' 36
After partial gastrectomy and gastrojeju- 
nal anastomosis (Billroth II) basal, and par­
ticularly postcibal, gastrin levels are dimin­
ished. On the other hand, partial gastrec­
tomy and gastroduodenal anastomosis (Bill­
roth I) affects the gastrin levels only slight­
ly,203 suggesting continued release of duo­
denal gastrin.
The relationship between recurrent ul­
ceration and postoperative gastrin levels has 
not been elucidated but when additional 
data are available, ulcer surgery may be­
come more rational.
Zollinger-Ellison Syndrome and Antral-
G-Cell Hyperplasia
Isenberg, Walsh and Grossman204 have 
recently published an excellent review of 
ZES. The disease is due to hypergastrinemia 
and the big and heptadecapeptide forms of 
gastrin account for the majority of the 
serum and tumour gastrin.31' 205 As ori­
ginally described, the syndrome included 
fulminant peptic ulcer disease, gastric hy­
persecretion and a non-y3-cell tumour of 
the pancreas, but the clinical spectrum may 
include moderate to severe peptic ulcer 
disease, diarrhea, steatorrhea, vitamin B12 
malabsorption and type I multiple endocrine 
adenomatosis.
With the discovery of hypergastrinemia 
with antral-G-cell hyperplasia (AGCH) as 
well as with pancreatic and duodenal 
gastrinomas the diagnostic work-up of ZES 
has been expanded. AGCH was originally 
described as ZES type I, with the classic 
form being called type II, but it is now 
clear that the two disorders are quite dis­
tinct and can be separated by biochemical 
and histologic criteria (Table V III).20°. 2 0 7  
A differential diagnosis based on clinical 
grounds, gastric acidity studies or fasting 
gastrin levels is fraught with difficulties, 
and the diagnosis is best established on the 
basis of elevated gastrin levels after infu­
sions of calcium, secretin or glucagon in
ZES and elevated gastrin levels after food 
in AGCH.207
Experience has shown that treatment for 
ZES should consist of total gastrectomy, 
the sole exception being an isolated duo­
denal gastrinoma (although metastases may 
be occult). Regression of metastatic tumour 
has been reported after total gastrectomy. 
If AGCH can be diagnosed accurately then 
antrectomy should be curative.207- 208
WDHA Syndrome
Watery diarrhea, hypokalemia and achlor­
hydria (WDHA syndrome, pancreatic chol­
era, Verner-Morrison syndrome) have been 
described with non-jS islet cell tumours200 
and retroperitoneal tumours.123 Achlor­
hydria is not invariable and the gastric 
acidity studies may be normal. The diar­
rhea may be cyclic or chronic. Other fea­
tures of the syndrome may include hyper­
calcemia, dehydration, hypokalemic nephro­
pathy, metabolic acidosis, flushing and glu­
cose intolerance (possibly due to hypokale­
mia). The patients tend not to have a fam­
ily history of endocrinopathy.
The hormone or hormones responsible 
have not been identified with certainty but 
must stimulate intestinal secretion while in­
hibiting gastric secretion. Suggested pos­
sibilities are secretin,209 G1P,116 VIP,112 
prostaglandins,134 gastrin plus glucagon210 
and a “CCK-like” hormone.211 At present, 
if the syndrome is a single entity (which it 
may not be), VIP is the most likely hor­
mone responsible for the symptomatology.
Surgery is the treatment of choice, but 
50% of the tumours are malignant and 
the majority will have metastasized by the 
time of surgery. Adrenocorticotropic hor­
mone (ACTH) and steroid therapy have 
been beneficial in controlling the diarrhea 
of inoperable patients.209
TABLE VIII.—Antral-G-Cell Hyperplasia v. 
Zollinger-Ellison Syndrome
Features A G C H Z E S
Fasting gastrin High Very high
Gastrin release by food 
Gastrin release by
Yes No
secretin No Yes
Antral G cells Hyperplasia Normal
Pancreatic D cells Normal Hyperplasia
Tumour No
or
tumour
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Alimentary Hypoglycemia
Postprandial hypoglycemia in the ab­
sence of pituitary, adrenal and liver dis­
ease or early diabetes is almost invariably 
of alimentary origin. Patients with rapid 
gastric emptying (either primary or sec­
ondary to gastric surgery) or enhanced glu­
cose absorption frequently develop alimen­
tary hypoglycemia. Postprandial hypogly­
cemia has also been described in patients 
with no obvious intestinal defects.151 The 
pathogenesis involves several nonexclusive 
variables including blood sugar, insulin 
secretion and enteroglucagon levels.
Although early hyperglycemia is common, 
it is not essential for the development of 
hypoglycemia.149 Likewise, hyperinsuline- 
mia may also be absent.212 Hyperentero- 
glucagonemia is a frequent finding.105
The pathophysiology probably involves 
varying combinations of hyperinsulinemia 
(secondary to hyperglycemia and incretin) 
and hyperenteroglucagonemia, which may 
inhibit the effects of pancreatic glucagon.105
Therapy involves the use of small, iso­
caloric, low carbohydrate meals to reduce 
hyperglycemia and to reduce induction of 
incretin149 and enteroglucagon, antichol­
inergics to delay gastric emptying, and small 
doses of phenformin (50 mg) to reduce 
glucose absorption and incretin secre­
tion.150, 151
Irritable Bowel Syndrome
Many of the patients seen by gastroen­
terologists are afflicted by the irritable bowel 
syndrome,213 a complex disorder of ab­
normal esophageal, small intestinal214 and 
colonic function.215 The disorder is rightly 
called a syndrome and probably represents 
the interaction of psychic, environmental, 
dietary and GI influences. The role of GI 
hormones in the pathogenesis of the dis­
order is not fully defined but Harvey and 
Read216 have recently demonstrated colonic 
motility disturbances and reproduction of 
symptoms during infusions of CCK in pa­
tients with the irritable bowel syndrome. 
Similar disturbances have been documented 
following presumed CCK release after oral 
magnesium sulfate administration.178 These 
experimental results and the clinical ob­
servation that symptoms frequently follow 
the ingestion of food suggest, very strongly,
that in some patients the irritable bowel 
syndrome may be secondary to disordered 
GI endocrinology. It is not yet known 
whether these patients are overproducing 
hormones or are just overly sensitive to 
normal hormone levels.
Study in the field of gastrointestinal endo­
crinology began over 70 years ago with the 
discovery of secretin by Bayliss and Starling. 
Interest in this field has grown rapidly in 
the last decade. In this review I have at­
tempted to summarize the current state of 
knowledge in gastrointestinal endocrinology 
and to indicate the relevance of this knowl­
edge to certain diseases of man. Much is 
still to be discovered.
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SELF-ASSESSM ENT
SESAP II QUESTION
507. Which of the following statements concerning serum gastrin levels is/are correct?
(1) They can be measured by radioimmunoassay using gastrin labeled with iodine-125
(2) They usually increase markedly in patients who have had antrectomy and vago­
tomy
(3) They are useful in identifying patients with the Zollinger-Ellison syndrome
(4) They are useful in investigating the possibility of residual vagal function after va­
gotomy
For this question one or more of the answers given above is correct. Your answer should be:
A if only 1, 2 and 3 are correct,
B if only 1 and 3 are correct,
C if only 2 and 4 are correct,
D if only 4 is correct,
E  if all are correct.
For the critique of Item 507 see page 372 of this issue.
(Reproduced by permission of the American College of Surgeons from SESAP II Syllabus: 
Surgical Education and Self-assessment Program No. 2.)
END-TO-SIDE ANASTOMOSES OF VEIN GRAFTS TO ARTERIES*
S. E. CARROLL, MD, FRCS[C], FACS
Although Linton1 described the use of a 
small venous tributary in the acute angle of 
end-to-side anastomoses between a vein 
graft and artery, I have found a larger tribu­
tary of greater length more convenient. If 
short transverse limbs, proximally and dis- 
tally, are added to the arteriotomy,2 a rec­
tangular anastomosis may be fashioned, 
helping to fix the intima (Fig. 1). This is 
particularly important in maintaining flow 
in both directions, for example, in the dis­
tal popliteal artery, below the origin of the 
anterior tibial branch. A larger venous tribu­
tary used in this way allows the surgeon to 
fashion the distal anastomosis with less risk 
of narrowing of the vein graft at the junction 
and gives extra length when this is crucial. 
Occasionally a tributary may be used at the 
distal end of the anastomosis, but in this 
situation the surgeon must be careful to re­
move valve tissue that may obstruct flow. 
With ingenuity a suitable tributary can al­
most always be found.
*From the department of surgery, St. Joseph’s 
Hospital, London, ON.
Reprint requests to: Dr. S. E. Carroll, Chief of 
surgery, St. Joseph’s Hospital, 268 Grosvenor 
St., London, ON N6A 1Y6.
V E I N  G R A F T  O P E N E D
Fig. 1.—End-to-side anastomosis, (a) Method 
of removing long saphenous vein (LSV) with 
tributary, (b) Opening proximal vein into tribu­
tary. (c) Variations in arteriotomy. (d) Completed 
rectangular anastomosis.
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GLIMPSES OF SURGICAL HISTORY:
J FOR SURGICAL JOURNALS
DAVID A. E. SHEPHARD
This journal is one of countless SU RGICAL  
JOURNALS published throughout the world. 
All have useful functions, and there are as many 
different types of surgical journals as there 
are functions and editors shaping them. As  
varied and as numerous as these journals are, 
however, their origin can be traced to one 
progenitor —  Philosophical Transactions —  
just as the many antibody-secreting lympho­
cytes develop from one cell type. The history 
of surgical journals well illustrates this series’ 
theme that surgeons’ nonsurgical colleagues 
have always shaped important developments in 
surgery.
The key developments in the history o f sur­
gical journals were these. In 1455, Gutenberg, 
in making available movable type, facilitated 
the spread of scientific knowledge. Dur­
ing the 16th and 17th centuries, many natural 
philosophers began to advocate the scientific 
method of enquiry and the direct observation 
of nature: Bacon advised his colleagues to 
“read not to contradict and confute, nor to 
believe and take for granted . . . but to weigh 
and consider” ; and Descartes recommended 
“the methodic doubt of everything” . Soon the 
importance of a single experiment or observa­
tion was recognized; books could no longer 
serve as means of rapid dissemination; corre­
spondence among scientists then assumed the 
function of speedy communication; however, 
letters were laborious to write in any number 
and, out of fear that they might too readily be 
criticized, letters tended to be sent to col­
leagues who would be unlikely to reject their 
content, which hardly served the Baconian 
method. So the idea that letters be printed and 
published periodically arose, an idea that re­
stored the principles behind scientific commu­
nication and also led to the development of 
the scientific periodical. The Transactions were 
first published in 1665. It was the first truly 
scientific journal and became the model for 
those that followed.
Scientific journals soon began to proliferate; 
they continue to do so. Their objective, how­
ever, has remained the same: today’s readers, 
among whom are innumerable surgeons, share 
the thinking of the president of the Royal 
Society in 1661, Robert Moray, who realized 
the importance o f  “communication among us 
of whatever knowledge may further for pos­
terity . . . most necessary o f studies”.
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EFFECTS OF AMBIENT AND STAGNANT HYPOXIA ON THE 
MECHANICAL AND ELECTRICAL ACTIVITY 
OF THE CANINE UPPER JEJUNUM*
A. MEISSNER, M D ,t K. L. BOWES, MD and S. K. SARNA, PhD!
The effects of ambient and stagnant hypoxia on 
the mechanical and electrical activity of the 
upper jejunum were studied in 32 anesthetized 
dogs. A 50 or 75%  reduction in oxygen content 
of inhaled air produced ambient hypoxia; su­
perior mesenteric artery (SMA) occlusion or 
thrombin-induced mesenteric thrombosis resulted 
in stagnant hypoxia. Induction of hypoxia was 
immediately followed by a transient increase 
in mechanical activity. A 50%  reduction in oxy­
gen content had no other effect. A  75% reduc­
tion in oxygen content resulted in a gradual 
decrease in electrical control activity (ECA) fre­
quency and in the disappearance of electrical 
response activity (ERA), and in jejunal contrac­
tions; however, ECA persisted until cardiac ar­
rest occurred after 30 to 45 minutes of hypoxia. 
Occlusion of the SM A  resulted in a significant 
decrease in contractile activity but ECA was not 
affected. Thrombin-induced mesenteric throm­
bosis produced rapid and irreversible disappear­
ance of both electrical and mechanical activities. 
Jejunal con.ractions and ERA are dependent 
upon an adequate oxygenated blood supply. ECA 
however, is highly resistant to reduction in oxy­
gen content of perfused blood and continues 
until perfusion stops.
Les effets de I'hypoxie ambiante et stagnante 
sur les activites mecaniques et electriques du 
jejunum superieur ont ete etudies chez 32 chiens 
anesthesies. line diminution de 50 a 75%  de la 
teneur en oxygene de I’air inhale a produit I’hy- 
poxie ambiante. L’occlusion de I’artere mesente- 
rique superieure (AMS) ou la thrombose mesen- 
terique provoquee par la thrombine ont resulte en
*From the department of surgery and Surgical- 
Medical Research Institute, University of Alberta, 
Edmonton, AB.
Presented at the annual meeting of the Royal Col­
lege of Physicians and Surgeons of Canada, Que­
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une hypoxie stagnante. L'induction de I'hypoxie a 
immediatement ete suivie d’une augmentation 
transitoire de I'activite mecanique. Une baisse 
de 50%  de la teneur en oxygene n’a produit 
aucun autre effet. Une diminution de 75%  du 
contenu en oxygene a entraine une baisse gra- 
duelle de la frequence de I'activite de contrdle 
electrique (ACE), et la disparition de I'activite 
de reponse electrique (ARE) et des contractions 
jejunales. Toutefois, I’ACE s ’est maintenue jus- 
qu'a I'arret cardiaque qui est survenu apres 30 
a 45 minutes d’hypoxie. L’occlusion de I 'A M S  a 
entraine une diminution significative de I’activite 
contractile mais I'ACE n'a pas ete affectee. La 
thrombose mesenterique provoquee par la 
thrombine a produit la disparition rapide et ir­
reversible, a la fois, des activites electriques 
et mecaniques. Les contractions du jejunum et 
I'ARE sont trse dependantes d'une reserve san­
guine adequate en oxygene. L’ACE cependant, 
est tres resistante a une diminution de la teneur 
en oxygene du sang de perfusion et persiste 
jusqu'a I'arret de la perfusion.
Two types of electrical activity can be 
recorded from the small bowel muscle of 
dogs and humans.1 The first, electrical con­
trol activity (ECA) (slow waves, pacesetter 
potential), is omnipresent and has a maxi­
mum frequency of 18 cycles/min in the 
duodenum of the dog. It controls the ap­
pearance in time and space of a second 
type: electrical response activity (ERA) 
(fast activity, spike potential). ERA initiates 
mechanical activity; that is, whenever ERA 
occurs at a site, the muscle at that site con­
tracts. ECA in the small bowel of the dog 
results from bidirectionally coupled relaxa­
tion oscillators.2
It has been suggested that ERA and ECA 
could determine the viability of bowel at 
laparotomy.3- 4 Ligation of mesenteric ves­
sels in the dog results in rapid disappear­
ance of both types of small bowel electrical 
activity. However, bowel ischemia may oc­
cur clinically in low-flow or hypoxic states 
without occlusive vascular disease.5 The re­
lative importance of flow and hypoxia in 
the generation of electrical activity is not 
known.
In this study, in attempting to determine
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the relative importance of flow and oxyge­
nation in the generation of electrical and 
mechanical activities of the small bowel, we 
compared the effects of ambient and stag­
nant hypoxia on small bowel electrical and 
mechanical activity in three groups of dogs.
M ethods
Anesthesia
Adult, healthy dogs (weight, 15 to 20 
kg) were fasted for 16 hours before each 
experiment. After induction of anesthesia 
with intravenous sodium pentobarbital (30 
mg/kg body weight) the dogs were intu­
bated with a plastic tube. To initiate con­
trolled respiration, succinylcholine chloride 
(30 mg) was administered intravenously, and 
the endotracheal tube connected to a res­
pirator. The dogs were ventilated 14 times/ 
min with 80% nitrogen and 20% oxygen 
at a tidal volume of 15 ml/kg body weight. 
Partial pressure of oxygen (Po2) in the 
inhaled gas mixture was equal to that of 
room air. Anesthesia was supplemented by 
sodium pentobarbital (10 mg/kg) and suc­
cinylcholine chloride (20 mg) as required.
Preparation of Jejunum and Monitoring
of Jejunal Activity
At laparotomy a loop of upper jejunum 
was exposed and three bipolar silver wire 
electrodes6 were implanted subserosally 
every 10 cm and oriented transversely to the 
bowel axis. The first pair of electrodes was 
placed 30 cm caudad to the ligament of 
Treitz. Contractile activity of the small 
bowel was recorded by extraluminal force 
strain gauges (R.B. Products, 153 Nautilus 
Dr., Madison, WI) aligned with the trans­
verse axis of the small bowel and sutured 
to the serosal surface at 10-cm intervals. 
The first was attached 3 cm distal to the 
first bipolar electrode. Recordings were 
made on an eight-channel Beckman R411 
dynagraph recorder. The myoelectric signals 
were filtered with upper and lower cut-off 
frequencies at 22 Hz and 1.6 Hz, respec­
tively.
Production of Ambient and Stagnant
Hypoxia
Group 1.—Ambient hypoxia was pro­
duced in this group by reducing the oxygen 
content of inhaled air by 50% (seven dogs) 
or 75% (seven dogs). Partial pressures of 
arterial and inhaled gas were determined 
before and every 30 minutes after oxygen 
reduction. The 50% reduction in oxygen 
lasted for 2 hours and the 75% reduction 
until cardiac arrest occurred. A continu­
ous recording of small bowel electrical and 
mechanical activity was made for 1 hour 
before and 2 hours after establishing am­
bient hypoxia.
Group 2.— In this group of nine dogs 
stagnant hypoxia was produced by occlud­
ing the superior mesenteric artery (SMA) 
for 2 hours by tightening a hemostatic 
snare, in the form of a polyethylene tube 
(ID, 0.86 mm; OD, 1.27 mm), placed 
around the vessel. The distal branch 
of the SMA was isolated (50 cm 
caudad to the ligament of Treitz) and can- 
nulated with an identical polyethylene tube, 
whose tip was positioned in the main trunk 
of the SMA. The femoral artery was then 
exposed and cannulated with a polyethylene 
tube (ID, 1.67 mm; OD, 2.41 mm). Each 
tube was connected to a transducer and 
hence to the recorder. Systematic and SMA 
blood pressures were recorded during the 
experiment. A decrease in blood pressure 
recorded in the distally placed polyethylene 
tube was interpreted as proof of SMA oc­
clusion (stagnant hypoxia). Electrical and 
mechanical activities were recorded for 1 
hour before, during the 2-hour period of 
artery occlusion, and for 1 hour after re­
lease of the snare.
Group 3.— In five dogs stagnant hy­
poxia was produced by direct injection of 
thrombin topical (150 NIH units/kg body 
weight; supplied by Parke-Davis & Co. 
Ltd., Montreal), which produced vein and 
SMA thrombosis. During the infusion (30 
to 60 s) the SMA and vein were occluded. 
Electrical and mechanical activities were 
recorded for 1 hour before and 2 hours 
after thrombin injection. Full-thickness seg­
ments of the intestinal wall were examined 
histologically at the end of the experiments.
To complete the experimental prepara­
tion, the small bowel was replaced in the 
peritoneal cavity, the laparotomy wound 
was closed, and the connecting wires and 
tubes were brought out through the suture
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line. Monitoring of the respiratory action 
throughout the study was by a transducer 
connected by a polyethylene tube to the 
respirator. A continuous electrocardiographic 
recording was made.
R esults
We recorded two types of electrical activity 
from the upper jejunum —  electrical con­
trol activity (ECA) and electrical response 
activity (ERA) (Fig. 1).
In the 1-hour basal period, ECA in all 
dogs was phase-locked' with an aboral di­
rection of phase lag and a mean frequency 
of 17.3 ±  0.91 cycles/min (±  SEM). Re­
sponse activity was usually noted when con­
tractions appeared, but, as the positions of 
electrodes and strain gauges were not ident­
ical, exact correlation did not always oc­
cur.
We recorded two patterns of contractile 
activity with the extraluminal force trans­
ducers,* the first consisting of groups of 
repetitive low-amplitude contractions ap­
pearing 4.8 ±  0.45 times per 5-minute re­
cording period (total duration, 56.0 ±  6.22 
s), and the second consisting of groups of 
high-amplitude repetitive contractions ap­
pearing 2.5 ±  0.31 times per 5-minute re­
cording period (total duration, 140 ±  16.1 
s).
Effects of Ambient Hypoxia (Group 1)
In all dogs, a 50% decrease in oxygen 
content of inhaled mixture (Po2, 67.5 mm 
Hg) resulted in a decrease in arterial Po2 
from 61.6 to 35.9 mm Hg. A 75% re­
duction in oxygen content of inhaled air 
(Po2, 37.4 mm Hg) resulted in a decrease 
in arterial Po2 from 66.7 to 16.8 mm. Hg.
Immediately after 50 and 75% reduction 
of oxygen in inhaled air, there were high- 
amplitude repetitive contractions (mean
* Quantitation of mechanical activity as recorded 
by external force transducers is difficult. Although 
ex-vivo quantitation of transducers is possible, the 
tension under which the gauge is sutured, the 
depth of sutures, slight deviations from the trans­
verse axis, and the state of bowel when the trans­
ducer is applied all profoundly influence their 
sensitivity. These factors obviate the extrapolation 
of ex-vivo results to the in-vivo situation. For the 
purpose of this investigation we arbitrarily clas­
sified mechanical activity into low amplitude 
«  1-cm deflection) and high amplitude (>  1-cm 
deflection).
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Fig. 1.—Types of electrical and mechanical ac­
tivity of upper jejunum during control period. 
Mechanical activity (SG1-SG3) appeared intermit­
tently either as groups of repetitive low-amplitude 
contractions (early part SGI) of repetitive high- 
amplitude (SG1-SG3) contractions. ECA (El - E3) 
appeared regularly 17.3 ±  0.91 times/min. ERA 
(early part E1-E3) was intermittently super­
imposed on ECA. Electrodes and strain gauges are 
at different positions (see text) so ERA and con­
tractions do not exactly correspond.
duration, 4.8 ±  0.33 min). ERA was as­
sociated with the contractions but ECA did 
not change.
Following the transient increase in me­
chanical activity and ERA, the patterns and 
frequencies of electrical and mechanical ac­
tivities in dogs subjected to a 50% reduction 
in inhaled gas oxygen content rapidly re­
turned to control levels. Systemic blood 
pressure did not change appreciably during 
hypoxia or after.
The 75 % decrease in inhaled oxygen con­
tent resulted in a progressive decrease in ECA 
frequency from 17.1 ±  0.47 cycles/min to 
11.9 ±  1.72 cycles/min 30 minutes after 
oxygen decrease (P <  0.05) (Fig. 2); ECA 
was, however, continuously present and 
phase-locked in an aboral direction, though 
at a lower frequency, until the heart stopped 
or fibrillated 42 ±  5.37 minutes after 75% 
oxygen decrease (Fig. 3). Systemic blood 
pressure was maintained until the heart 
slowed or its rhythm became irregular. 
After the initial transient increase in con-
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Fig. 2.—Mean ECA frequency before (C) and 
after either oxygen reduction or occlusion of the 
superior mesenteric artery (SMA). Vertical lines in­
dicate ±  SEM. Arrow indicates release of occlu­
sion or reestablishment of normal oxygen level in 
inhaled air. X indicates recorded values 10 to 15 
minutes before arrest of heart action.
tractile activity, low- and high-amplitude 
contractions and ERA disappeared. ERA 
and contractions were absent for the re­
mainder of the experiment.
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Fig. 3.—Electrical and mechanical activity of 
jejunum at time of circulatory arrest after 75% 
reduction in oxygen content of inhaled air. Note 
absence of contractile activity and persistence of 
ECA until moment of arrest.
Effects of SMA Occlusion (Group 2)
Traction on the plastic tube placed 
around the SMA produced a striking de­
crease in blood pressure within its branches. 
Throughout the occlusion period, however, 
the mean blood pressure in the SMA re­
mained at 15 to 20 mm Hg. Immediately 
after occlusion there were high-amplitude 
repetitive contractions associated with ERA 
for 3.5 ±  0.75 minutes. ECA did not 
change. After this brief interval of increased 
contractile activity, there was a period of 
diminished activity that persisted to the end 
of the experiment (Fig. 4). Low-amplitude 
repetitive contractions were less common, 
appearing 2.5 ±  0.44 times per 5-minute 
period (P <  0.05). High-amplitude repetitive 
contractions diminished slightly but not sig­
nificantly from a basal incidence of 2.7 ±  
0.57 to 1.3 ± 0 .4 4  times per 5-minute 
period. The total duration of the high-am­
plitude contractions, however, increased 
from 110.4 ±  21.3 to 210.1 ±  18.2 seconds 
(P<0.05). Throughout the experiment ECA 
remained phase-locked in an aboral direction 
with a frequency of 16.8 ±  0.31 cycles/min.
After release of tape around the SMA 
and restored full blood flow, contractile ac­
tivity Returned to the pattern seen in the 
control period.
Effects of SMA and Vein Thrombosis
(Group 3)
Direct administration of thrombin into 
the SMA produced intravascular coagula­
tion in all small-diameter arteries and capil­
laries of the small bowel and in all tribu­
taries of the superior mesenteric vein. The 
small bowel became cyanotic and hemor­
rhagic. There were diffuse subserosal and 
submucosal hemorrhages with extravasation 
of blood into the small bowel lumen.
A transient period (2.3 ±  0.24 min) of 
high-amplitude repetitive contractions im­
mediately followed the thrombin injection. 
Then contractile activity and ERA disap­
peared and were not recorded again (Fig. 5). 
In four dogs ECA disappeared 6.5 ±  0.91 
minutes after thrombin injection but in one 
it ceased 45 minutes after mesenteric throm­
bosis. ECA remained phase-locked and the 
direction of the phase lag was always aboral 
until it ceased.
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BEFORE SMA OCCLUSION 30 MIN AFTER
Fig. 4 .—Mechanical activity of jejunum before and 30 minutes after occlusion of SMA.
D i s c u s s i o n
In this study ambient hypoxia produced 
by decreasing the oxygen content of inhaled 
air caused a transient increase in jejunal me­
chanical activity. When the oxygen reduc­
tion was minor (50%), normal contractile 
activity rapidly returned. When the oxy­
gen reduction was greater (75%), all me­
chanical activity rapidly disappeared. Stag­
nant hypoxia, produced in these experiments 
by SMA occlusion, was also followed by 
an initial transient increase in mechanical 
activity. Thereafter, contractions persisted 
at a greatly reduced rate. SMA pressure fol­
lowing ligation persisted at 15 to 20 mm Hg 
indicating the presence of substantial col­
lateral circulation through the pancreatico­
duodenal arcade.
Throughout all of the procedures ECA
RESP.
Fig. 5.—Jejunal electrical and mechanical activity before and after massive intravascular coagu­
lation produced by injection of thrombin into SMA.
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persisted and remained phase-locked in an 
aboral direction. Only after a 75% decrease 
in oxygen content of inhaled air did the 
frequency decrease. Even then ECA per­
sisted until all flow ceased at the time of 
cardiac arrest. When the injection of throm­
bin into the SMA produced rapid cessation 
of flow ECA, ERA and all mechanical ac­
tivity disappeared.
The persistence of ECA until the com­
plete arrest of circulation indicates that it is 
comparatively resistant to hypoxia. ECA is 
primarily a myogenic function and does 
not require nervous or hormonal input for 
its generation. It is dependent upon the 
integrity of the cellular sodium pump.7 
Upon complete arrest of blood flow, rapid 
changes in cell membrane permeability, elec­
trolyte concentration, and metabolite accu­
mulation occurred. These changes probably 
resulted in the disappearance of ECA.
Mechanical activity, on the other hand, 
appears to be more sensitive to changes in 
arterial Po2. It is difficult to attribute such 
rapid changes to neural degeneration; they 
are more likely due to changes in mem­
brane permeability produced by hypoxia.
It has been suggested4 that the recording 
of electrical activity at operation may be of 
value in determining the viability of bowel 
in low-flow states and after arterial or 
venous thrombosis and embolism. Recording 
at the time of operation, however, may be 
misleading. This study indicates that a 
normal jejunal ECA frequency can persist 
in spite of severe hypoxia. In addition,
small bowel ischemia may progress 
following laparotomy. It has been suggested 
that all patients operated on for ischemic 
bowel disease have a second laparotomy 24 
hours later to check for progression of the 
ischemia. The use of electrodes implanted 
into the small bowel with recording in the 
postoperative period in such patients may 
obviate the need for a second operation. 
Electrodes have been implanted into the 
stomach of patients undergoing laparotomy 
by Sarna, Bowes and Daniel6 without side 
effects. The clinical application of small 
bowel electrical activity recording in ische­
mic bowel disease may take this form.
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MALADIE DE PAGET DU SEIN CHEZ L’HOMME
MAURICE FALARDEAU, MD, FRCS[C],* MLADEN RUSNOV, MD, FRCS[C1+ 
et ROBERT LESAGE, MD, FRCP[C]i
Un homme de 78 ans se presente pour une ma- 
ladie de Paget du sein. II s’agit d’une entite 
rare et nous croyons presenter le 22eme cas 
prouve histologiquement bien qu'en 100 ans 
environ 40 articles et moins de 50 observations 
aient ete publies.
A la lumiere de I’experience recente, les au­
teurs ont opte pour une chirurgie plus limitee 
soit une mastectomie totale avec evidemment 
axillaire plutot qu’une mastectomie radicale clas- 
sique puisqu'il n'y avait ni masse sous-jacente 
cliniquement decelee ni adenopathie.
De plus, retenons que toute lesion eczema- 
toide du mamelon qui persiste plus de 2 se- 
maines ou qui est unilateral devient suspecte 
de malignite et devrait alors etre biopsee. t
The case of a 78-year-old man with Paget's dis­
ease of the breast, described herein, appears to 
be only the 22nd histologically proven case of 
this rare condition; in over 100 years less than 
50 cases have been reported. Since this patient 
had no underlying tumour or nodal involvement 
the operation consisted of total mastectomy 
with removal of axillary nodes only, rather than 
the classical radical mastectomy. All eczematoid 
lesions of the areola of the breast that persist 
for more than 2 weeks or are unilateral should 
be considered Paget’s disease until proven 
otherwise by biopsy.
En 1874 Sir John Paget1 a decrit pour la 
premiere fois la maladie de Paget du sein. 
La description de Paget s’ajoutait a l’ob- 
servation de Velpeau de 1859 mais, selon 
Sekigughi,2 c’est Erichsen qui, en 1879, 
proposat que cette entite porte le nom de 
maladie de Paget. Nous rapportons un cas 
de cette affection chez Fhomme.
Affection peu frequente, puisque le can­
cer de la glande mammaire est environ 100 
fois plus rare chez le sexe masculin que
*Professeur agrege, departement de chirurgie, Uni­
versity de Montreal. Membre actif senior, Hopital 
Notre-Dame, Montreal, PQ.
tEx-resident en charge, departement de chirurgie, 
Hopital Notre-Dame, Montreal.
tProfesseur adjoint de clinique, departement de 
pathologie, Universite de Montreal. Membre actif 
senior, Hopital Notre-Dame, Montreal.
Les demandes de tires-a-part doivent etre adres- 
sees au: Dr. Maurice Falardeau, departement de 
chirurgie, Hopital Notre-Dame, 1560, rue Sher­
brooke, est, Montreal, PQ H2L 4M1.
chez le sexe feminin3"6 et que la maladie 
de Paget constitue de 1 a 3% de tous les 
cas de neoplasie mammaire,4’ 7- 8 on s’at- 
tend a trouver un homme atteint de cette 
maladie sur 3 a 10 000 cas de cancer du 
sein. Au Centre d’Oncologie de l’Hopital 
Notre-Dame, sur 5076 cas de neoplasie du 
sein qui ont ete observes sur une periode 
de 32 ans, on compte 7 femmes atteintes 
de maladie de Paget et seulement 2 hom­
ines. Un de ces cas a ete opere initialement 
ailleurs et nous rapportons ici le second.
En 100 ans, environ 40 articles et une 
quarantaine d’observations ont ete publies 
dans la litterature mondiale sur ce sujet. 
Toutefois, selon Crichlow et Czernobilsky,4 
seulement 11 cas authentiques auraient ete 
decrits jusqu’en 1969. Ces auteurs en ont 
rapporte deux autres, auxquels viennent 
s’ajouter les cinq cas de Coley et Kuehn9 
et d’autres publies par Suzuki et Kubota,10 
Von Bartel et Wagner,11 O’Grady et Mc- 
Divitt," Nance et collegues,8 et Haagen- 
sen.12 Enfin, celui que nous presentons ici, 
serait done le 22eme.
P r e s e n t a t io n  C l in iq u e
Un homme, age de 78 ans, est admis dans 
le service d’opthalmologie en mars 1974. Entre 
1961 et 1969, il avait ete hospitalise a quatre 
reprises pour un infarctus du myocarde, une 
periarthrite de Fepaule droite, une cholecystite 
et une cataracte. En aucun moment, il ne fut 
mention de lesion au sein.
A l’examen physique, on decouvre une le­
sion squameuse du sein droit. En retrospective, 
le malade raconte que, depuis une dizaine d’an- 
nees, il accuse localement un prurit modere 
et que le mamelon saigne en certaines occa­
sions.
Le dermatologiste consulte note une plaque 
erythemateuse, bien delimitee, squameuse, in- 
teressant tout le mamelon droit, sans adherence 
au plan profond, mesurant environ 3 cm de 
diametre (Fig. 1); il n’y a pas de masse sous- 
jacente. Aucun ganglion axillaire n’est palpe. 
Le sein gauche est normal.
La mammographie ne decele ni gynecomas- 
tie ni lesion tumorale et l’etude radiologique du 
squelette ne montre aucun signe de metastase 
osseuse. On procede alors a une biopsie qui 
demontre une maladie de Paget du sein. Le
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Fig. 1.—Aspect clinique d’une maladie de Paget.
malade subit ensuite une mastectomie simple 
(totale) avec evidemment ganglionnaire axil- 
laire.
Le specimen anatomo-pathologique nous 
montre un fragment provenant du mamelon ou 
l’epiderme est infiltre par de larges cellules a 
cytoplasme clair avec des noyaux irreguliers 
et parfois mitotiques (Figs. 2 et 3). Au niveau 
de la glande mammaire sous-jacente, on note 
des canaux remplis par une proliferation de 
cellules epitheliales neoplasiques. II n’y a pas 
d’envahissement extracanaliculaire (Fig. 4). II 
n’y a pas de metastase au niveau des ganglions 
axillaires.
L’evolution postoperatoire est normale et 28 
mois plus tard le malade est asymptomatique.
D iscussion
Sur le plan clinique, le symptome le plus 
frequent de la maladie de Paget du sein 
est l’ecoulement du mamelon avec excoria­
tion et ensuite ulceration. Le malade se 
plaint la plupart du temps d’un prurit leger. 
On retrouve un eczema du mamelon et de 
l’areole avec ou sans masse sous-jacente et 
l’envahissement ganglionnaire est rare chez 
1’homme. Sur les 13 cas colliges par 
Crichlow et Czernobilsky,4 9 presentaient 
une masse et 5 seulement avaient une at- 
teinte des ganglions.
Les changements cutanes precedent-ils 
l’apparition de la neoplasie ou en sont-ils 
une manifestation secondaire? Treves13 en 
1954 rapporte un cas ou la maladie est 
demeuree localisee a la peau pendant 14 
ans sans qu’on n’ait pu deceler d’epithelioma 
de la glande ni de metastase ganglionnaire 
lors de la mastectomie. Des delais de 25 et 
30 ans ont ete rapportes respectivement par 
Sekigughi2 et Fabry et Trautmann.2
De plus, selon Dockerty et Harrington14 
et Coley et Kuehn,9 on peut retrouver une
Fig. 2.—Envahissement de l’epiderme par des cellules de Paget (hematoxyline et eosine; le gros- 
sissement fx 1601 a ete reduit de 25%).
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Fig. 3. Cellules de Paget (hematoxyline et eosine; le grossissement [x 4001 a ete reduit de 25%).
maladie de Paget du mamelon a un stade 
pre-clinique, sans lesion eczemateuse ma- 
croscopique du mamelon mais avec des cel­
lules de Paget typiques a 1’histologie.
Enfin une maladie de Paget du sein doit 
toujours faire rechercher attentivement une
neoplasie mammaire sous-jacente a la le­
sion du mamelon.
En pratique toute lesion eczematoide ou 
excoriation du sein qui persiste plus de 2 
semaines doit faire 1'objet d’une biopsie. 
On doit considerer toute lesion unilateral
Hg. 4.—Proliferation neoplasique bien localisee a l’interieur des canaux galactophores (hematoxy­
line et eosine; le grossissement [x 160] a ete reduit de 25%).
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comme une maladie de Paget jusqu’a preuve 
du contraire. La mammographie constitue un 
adjuvant precieux pour deceler la presence 
ou Fabsence d’une masse sous-jacente.
Le diagnostic differentiel est a faire avec 
la maladie de Bowen, l’adenomatose beni- 
gne du mamelon, Feczema simple, la folli- 
culite, le melanome amelanique, la croute 
banale de Fhygiene defectueuse et la neo- 
plasie ulceree du sein envahissant le ma­
melon.
Sur le plan histopathologique, la maladie 
de Paget consiste en une infiltration de l’e- 
piderme par de larges cellules a cytoplasme 
clair dites cellules de Paget mais decrites 
par Darter15 en 1889 et le diagnostic defi- 
nitif depend de la presence de ces cellules de 
Paget.
Ceci nous amene a etudier la relation 
entre les changements epidermiques du ma­
melon et le cancer du sein sous-jacent. II 
s’agit d’un envahissement de l’epiderme par 
des cellules neoplastiques d’origine canali- 
culaire.4 Les cellules tumorales envahissent 
progressivement les canaux galactophoriques 
puis l’epiderme de surface.
Le traitement de cette maladie est des 
plus controversy. Jusqu’a recemment, seule 
la mastectomie radicale avec greffe3’ 10- 13, 
16 cutanee etait acceptee comme traitement 
valable. Des articles tout recents mettent en 
doute cette assertion.12’ 17
La rarete de cette lesion chez Fhomme 
interdit en fait d’adopter une attitude rigide.
Dans Fobservation que nous rapportons 
ici, le patient n’a subi qu’une mastectomie 
totale avec evidemment axillaire. Selon les 
resultats histologiques, il semble bien qu’il 
n’y avait pas d’indication de faire davantage 
puisque les ganglions axillaires preleves 
etaient indemnes d’envahissement.
D’une fa?on generate, le pronostic d’un 
cancer du sein chez Fhomme serait moins 
bon.18’ 19 Le milieu hormonal male en 
serait-il responsable? Les hommes consul- 
teraient-ils apres un plus long delai? Enfin 
le sein de Fhomme etant plus petit, l’enva- 
hissement des structures avoisinantes se fe- 
rait-il plus rapidement?
Holleb, Freeman et Farrow17 croient que 
le pronostic a pu sembler moins bon parce 
que tres peu de neoplasies du sein sont 
observees chez Fhomme et que les referen­
ces valables sont encore plus rares.
Nous croyons que la maladie de Paget 
avec masse palpable ne differe que tres peu 
des autres cancers du sein et doit etre traitee 
comme tel. Cependant, si la presence d’une 
tumeur ne peut etre decelee dans le sein ni 
cliniquement ni a l’aide de la mammogra­
phie et si l’extension de l’erosion du ma­
melon ne depasse pas l’areole, une mastec­
tomie simple (totale) doit etre consideree 
comme un traitement definitif, particuliere- 
ment chez les patients avec un risque ope- 
ratoire elevee.
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The Effect of
TVasy lol
in
Acute
Pancreatitis
Results
1
extent0 *" W3S show n to reduce mortality in acute pancreatitis to a significant 4 !
C ou rse  o f illn e s s
G ro u p  A (T ra s y lo l) G ro u p  B (P la c e b o )
No. % No. %
M ild 30 56.6 22 42 3
M od e ra te 13 24.5 9 1 7 ^
S evere
D ied
6
4
11.3
7.5
8
13
15.4
25.0
T o ta l 53 99.9 52 100.0
Placeb0................................................  25.0% Mortality
Trasy|Ql®...................................................  7.5% Mortality
Because the number of deaths were reduced, the spectrum of the disease 
as a whole was altered.” *
Trapnell’s recent double-blind clinical trial 
involving 105 patients confirmed the 
effectiveness of Trasylol in acute 
pancreatitis. In addition to reducing 
mortality and altering the spectrum of the 
disease, Trasylol largely abolished the usual 
effect of increasing age in this condition. 
Trasylol should be given concurrently with the 
usual measures for the treatment of 
pancreatitis, such as pain relief, 
fasting, gastric suction, etc. “ It 
(Trasylol) can therefore now be 
regarded as a drug which is both 
effective and beneficial in the 
treatment of acute pancreatitis.” *
*Trapnell, J.E. et al, British 
J. Surg., March 1974.
The Effect of
Trasylol
in
Hyperfibrinolytic
Hemorrhages
Trasylol, in its role as an 
antifibrinolytic agent, inhibits 
both plasmin and the 
plasminogen activator.
Synthetic antifibrinolytic 
agents inhibit only the 
plasminogen activator.
Trasylol is indicated for primary and generalized, secondary 
hyperfibrinolytic hemorrhages with and w ithout the shock 
syndrome. Secondary hyperfibrinolysis follow ing 
/ * * \  intravascular clotting may require heparin and/or 
fibrinogen replacement in addition to Trasylol. 
With Trasylol, the antifibrinolytic agent with 
simultaneous anti-coagulant (anti-throm boplastic) 
effect, there will not be a dangerous shift 
in the equilibrium between 
the clotting and the lysis system 
in favour of coagulation. 
Synthetic antifibrinolytics 
are contraindicated if there is 
evidence of active intravascular 
coagulation. Trasylol is indicated 
in all cases of hyperfibrinolysis, 
whether a differential diagnosis 
has been made or not.
FBA Pharmaceuticals Ltd.
Distributed by:
Boehringer Ingelheim (Canada) Ltd.
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Trasylol
•  increases the chances 
of survival in acute 
pancreatitis
•  prevents the enzymatic 
release of toxic 
polypeptides and kinins
•  stops hyperfibrinolytic 
hemorrhage
Indications and Dosage
Hyperfibrinolytic Hemorrhage 
These c o n d itio n s  o c c u r in surgery , 
including open heart surgery, prostatic 
surgery and patho log ica l obste trica l 
bleeding conditions, such as in abruptio 
placentae.
Initial dosage: 200,000 — 500,000 K.I.U. 
of which 200,000 K.I.U. should be given 
by intravenous injection (a t a rate not to 
exceed 5 ml per minute), the rest if neces­
sary by slow  infusion. A dm in istra tion 
should  be continued up to 1,000,000 
K.I.U. per day until the hemorrhage has 
been arrested.
Pancreatitis
Initial dosage: 100,000 — 200,000 K.I.U. 
to be followed by 100,000 K.I.U. every 
six hours fo r a period of 4-5 days. The 
drug is administered either by intraven­
ous in jection (at a rate not to exceed 5 
ml per minute) or by slow infusion. 
Warnings and Precautions 
Trasylol is a polypeptide and thus may 
act as an antigen. Although adverse reac­
tions due to hypersensitivity have been 
described infrequently, this possibility 
should always be kept in mind. In patients 
w ith a h istory of hypersensitiv ity, the 
usual precautions for the prevention and 
arrest of a lle rg ic  reactions should be 
observed prior to the adm inistration of 
Trasylol.
Availability
Trasylol (aprotinin) is available in 10 ml 
am puls co n ta in in g  100,000 K.I.U . in 
boxes of 5 ampuls.
Trasylol® Product Monograph is available 
on request.
The object of
Trasylol:
Control of proteolytic enzymes.
FBA Pharmaceuticals Ltd.
Distributed by: __
Boehringer ingelheim (Canada) Ltd.
2121 Trans Canada Highway, Dorval, P.Q. H9P 1J3
DIRECTIVES A U X  CONTRIBUANTS
Toute communication initiale doit etre adres- 
see au Coredacteurs, CP 8650, Ottawa, ON 
K1G 0G8 sous la mention: “Le journal cana- 
dien de chirurgie”.
Manuscrits. Les texts originaux des articles 
et des autres communications y compris un 
nombre limite de rapports sur des cas spe- 
ciaux doivent etre rediges en double exem- 
plaire, en franpais ou anglais, et accompagnes 
d’une lettre demandant leur publication dans 
le Journal. Veuillez les dactylographier sur une 
seule face d’une feuille normal avec double 
interligne et grandes marges.
Illustrations. Les illustrations telles que des 
photographies d’appareils cliniques, des ra- 
diographies, des photomicrographies, des gra- 
phiques et des digrammes doivent etre four- 
nies sous la forme d’epreuves sur papier glace 
sans montage, les bordures intactes, d’un format 
ne depassant pas 12 x 17 cm. Chaque illustra­
tion doit etre munie d’une legende dactylo- 
graphiee sur une page separee du texte de 
1 article. S il s’agit d’une photomicrographie, 
expliquez le contraste et l’echelle de l’agran- 
dissement. Les lettres qui servent a identifier 
les elements d’une illustration doivent etre d’u­
ne dimension suffisante afin de demeurer visi­
bles lorsque les necessites de l’impression im- 
posent une reduction de l’image fournie. II 
ne faut pas qu’on puisse identifier un patient 
grace a une illustration a moins qu’il n’y ait 
expressement consenti par ecrit; faute de per­
mission les traits de sa physionomie doivent 
etre obliteres. Les illustrations en couleur ne 
seront publiees qu’aux frais de leur auteur. 
Si 1 illustration provient d’une autre source que 
celle de 1 auteur, il convient d’obtenir tant de 
Tauteur que de l’editeur de l’ouvrage dont elle 
est tiree, 1 autorisation de s’en servir aux fins 
de la publication.
Tables. Il faut en les etablissant se conformer 
au format rectangulaire du Journal et les 
rediger sur des feuilles separees du texte, une 
table par feuille.
References. Celles-ci doivent etre citees dans 
le texte au moyen d’un chiffre et groupees 
dans 1 ordre a la fin de votre article en vous 
conformant a la maniere de faire adoptee par 
ce Journal. Les references a des periodiques 
doivent etre conformes a celles qu’adopte 
VIndex Medicus.
Un resume qui ne doit pas depasser 125 mots 
doit accompagner chaque article sur une page 
separee.
Une epreuve en placard sera adressee a l’au- 
teur de 1 article avant sa parution; on ne peut 
autoriser que de legeres retouches. Ce n’est 
qu au moment de restituer ces epreuves d’au- 
teur au Journal qu’il y aura lieu de passer 
commande de reimpression.
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ABSTRACTS OF PAPERS PRESENTED AT THE ANNUAL MEETING 
OF THE CANADIAN ORTHOPAEDIC RESEARCH SOCIETY, 
HELD IN OTTAWA, ONTARIO, MAY 25 AND 26, 1975
1. Augmentation of Bone H ealing by 
Supplemental Direct-Current 
Electricity
D. A. MacKenzie and C. Knowles
Because the Harris fracture-healing model 
produces nonunion it is ideal for quantitat­
ing the ability of supplemental direct-current 
(DC) electricity to augment the rate and ca­
pacity of fracture healing.
In this preliminary study transverse single 
saw cuts were created at the junction of 
the proximal and middle thirds of the radius 
in a control group of mature dogs. Although 
these fractures were bilateral and unfixed, 
the radii were reasonably stable and the 
animals were able to walk on the 1st post­
operative day. The reliability of the model 
was confirmed by creating bilateral saw 
cuts in six mature dogs. In all six dogs well- 
established, bilateral nonunion was demon­
strated radiographically. Histologic exami­
nation confirmed the presence of cartilage 
in the gap.
The same procedure was performed in 
a second group of four dogs, but in addition 
they received 20 /xA of continuous DC cur­
rent on one side, a dummy lead being 
placed in the medullary canal on the other 
(control) side. In three dogs, bone union was 
demonstrated on non-screen radiographs and 
was confirmed by histologic examination.
In a third group of 10 dogs, a pulsed DC 
current unit was implanted. In the six dogs 
sacrificed, there were definite signs of ad­
vanced healing on the experimental side as 
judged by non-screen radiographs and his­
tologic examination.
Department of surgery,
Montreal Children’s Hospital,
Montreal, PQ.
2. Aurosomes in Rabbit Articular 
Cartilage
A. F. Oryschak and F. N. Ghadially
Although gold salts are used in the treat­
ment of rheumatoid arthritis, little is known 
about the morphology and distribution of 
gold in articular tissues. The aim of this
study was to find out whether gold injected 
into the joint enters articular cartilage.
Sodium aurothiomalate (Myochrysine) 
injected into the knee joints of rabbits pro­
duced lysosomes (aurosomes) of a char­
acteristic morphology in the chondrocytes of 
articular cartilage. Such lysosomes are mor­
phologically distinct from others and from 
those present in joints injected with sodium 
thiomalate. With the aid of electron-probe 
x-ray analysis, gold and phosphorus were 
demonstrated in the aurosomes.
Numerous coated vacuoles also developed 
in the chondrocytes in joints injected with 
sodium aurothiomalate. It is thought that 
these vacuoles are involved in the transport 
of a gold-protein complex and that the auro­
somes evolved from the coalescence of such 
vacuoles with primary lysosomes.
Department of pathology,
University Hospital,
Saskatoon, SK.
3. Biofeedback Applied to Patients 
with Above-Knee A mputations
G. R. Fernie, J. P. Kostuik, C. McLaurin 
and B. Zimnicki
In training a patient with an above-knee 
amputation it is important to teach him to 
ensure that the knee joint of the prosthetic 
limb is fully extended before he places any 
weight upon it. If not he will be unstable 
and may fall. A  simple device helps train 
amputees in this aspect of walking. The de­
vice consists of a buzzer that sounds when 
the knee is flexed and is silent when the 
knee is fully extended. It has been used 
effectively for over a year at the amputee 
centre of the Toronto Hospital. Biofeedback 
techniques are being applied to correct other 
common errors made by amputees. In addi­
tion to aiding the physiotherapist in the 
training sessions, these devices also permit 
patients to use their time in hospital better 
by enabling them to exercise in the absence 
of the physiotherapist but still with a degree 
of automatic supervision.
The experienced amputee might benefit 
by the provision of continuous proportional 
feedback of the angle of flexion of the knee
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joint, so a second device has been designed 
to fulfil this need. This system uses tactile 
stimulation of the skin of the stump.
Amputee Research Centre,
Toronto Hospital,
Weston, ON.
4. Blood Supply of the Cortex in 
Growing and A dult Bone
A. Trias
The role of the arterial and venous systems in 
the bone cortex was examined in the femora 
of dogs and rabbits. Study of the anatomy 
revealed two distinct vascular networks. The 
first, seen only in young growing bone, is a 
functional network of vessels of capillary 
calibre, which form rectangular meshes, 
longitudinally oriented, and which do not 
divide by dichotomy but anastomose with 
each other with no change in calibre. This 
system is continuous with the deep layer of 
the periosteum and that of the endosteum 
and permeates the whole cortex. As the 
haversian systems are formed, a second, 
new, system appears —  the supply system. 
It consists of arteries and veins radiating 
from the bone marrow, penetrating the 
cortex in a straight line and then branching 
in arborescent fashion. The vessels anasto­
mose freely with the mesenchymal system.
In the younger cortical bone, when the 
functional system prevails, the flow appears 
to be centripital. In adult bone the arterial 
cortical flow via the supply system is cen­
trifugal, but the blood returns centripitally 
to the marrow before leaving the bone main­
ly through metaphyseal veins. The changes 
in cortical circulation from growing to adult 
bone reflect its changing histologic struc­
ture.
Department of orthopedics,
Centre Hospitalier Universitaire,
Universite de Sherbrooke,
Sherbrooke, PQ.
5. Collagen A rchitecture of Normal 
AND OSTEOARTHRITIC HUMAN ARTICULAR 
Cartilage
R. U. Repo, K. Newland and L. Johnston
The architecture and the morphologic disin­
tegration of collagen in osteoarthritic arti­
cular cartilage was investigated by scanning
electron microscopy in 14 tibial plateaus (7 
were normal by the criteria of Collins).
The collagen was exposed by partial re­
moval of proteoglycans with 4 M guanidi- 
nium hydrochloride and was dehydrated by 
sublimation with camphene to minimize 
artefactual distortion of the tissue.
The study of normal articular cartilage 
showed that the tangential zone of collagen 
is arranged generally along the split lines of 
Hultkrantz, but below this the split lines 
do not correspond to any recognizable col­
lagen orientation.
Osteoarthritic specimens demonstrated 
deep microfissures and were direct exten­
sions of fibrillation defects seen macro- 
scopically. Selected specimens of early os­
teoarthritic tibial plateaus demonstrated 
microscopic fissuring of the collagen frame­
work in planes perpendicular to the split 
lines of Hultkrantz, suggesting that these 
fissures may represent fatigue failure of 
collagen occurring near the free edge of 
the meniscus and the weight-bearing por­
tion of the plateau.
Department of surgery,
University of Western Ontario,
London, ON.
6. Collagen Polymorphism in Ossifying 
Bony Rudiments of the Human Fetus
D. J. Gates and W. M. Rigal
Different types of collagen exist in bone 
and cartilage. The synthesis of bone (type 
I) and cartilage (type II) collagens in cul­
tured bony rudiments of the human fetus 
was investigated as a preliminary study of 
collagen polymorphism in pathologic bone 
formation in man. Normal long-bone rudi­
ments from 6- to 16-week-old fetuses were 
cultured under lathyritic conditions, in vitro, 
for 12 hours in the presence of 14C-lysine 
and 3H-proline. The various developmental 
regions were dissected from the explants 
after freezing in liquid nitrogen, then sub­
jected to a sequential extraction procedure 
designed to facilitate solubilization and re­
moval of the newly synthesized (lathyritic) 
and pre-existing, unlabelled collagens. Ex­
tracts containing labelled and unlabelled 
collagens were combined after dialysis, and 
collagen subunits were separated on carbo- 
xymethyl-cellulose cation exchange columns
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using a linear sodium chloride gradient. 
Peaks of radioactivity were identified by 
collagen subunit type, and relative con­
centrations of bone and car­
tilage ([a1(II)]3fl) collagens were calculated 
for each region of the explants. Changes in 
the molar ratio of a 1:a2 in calcified and 
noncalcified regions indicate that the appear­
ance of type I collagen is a prerequisite to 
calcification in the ossifying bony rudiments 
of the human fetus.
Department of surgery,
University of Alberta,
Edmonton, AB.
7. Comparison of Joint-Force Loading 
Patterns for Varus, Valgus and
F lexion D efo rm ities  at the Kne e
/. 7. Harrington
A bioengineering analysis of force trans­
mission at the knee was carried out by the 
dynamic three-dimensional technique of 
Morrison, and the results were compared 
with those calculated from a static frontal 
plane analysis. Varus, valgus and flexion 
deformities were assessed.
Major differences occur for joint-force 
magnitude and location of the centre of 
joint pressure at the knee using the two 
different methods of analysis. The discre­
pancies are most apparent for flexion de­
formities.
In valgus limbs, the centre of joint pres­
sure may be located in the medial joint 
compartment for an appreciable portion of 
the stance phase of the gait cycle, and at 
periods when joint-force loading is maximal.
These results suggest that the centre of 
joint-force pressure cannot be predicted ac­
curately by static analytical methods. The 
rationale of performing high tibial osteo­
tomies based on static frontal plane calcula­
tions is questionable.
Since an osteotomy to provide ideal joint 
loading throughout the stance phase of the 
gait cycle cannot be designed, the most 
practical method of osteotomy might be 
simple, anatomical restoration of knee align­
ment.
Department of surgery,
Toronto East General & Orthopaedic Hospital, 
Toronto, ON.
8. E ffe c t s  o f  E lectrical Stim u l a t io n  
on B one  G rowth In  V itro and  on
F racture H ealing
W. G. de Haas* and J. Watson f
A  noninvasive technique of electrical stimu­
lation of bone growth and fracture healing 
was studied in vitro and in a patient with 
a fracture. The growth of embryo chick 
tibias was found to accelerate in pulsed 
magnetic and pulsed electric fields, and 
healing in osteotomized radii in rabbits was 
likewise accelerated, though inconsistently, 
when radii were subjected to a pulsed mag­
netic field. In the case of the patient, a 50- 
year-old man with a post-traumatic pseu- 
darthrosis of the tibia, treatment in a pulsed 
magnetic field for 6 weeks resulted in bone 
union 6 months later.
The principle use of a pulsating magnetic 
field to induce an electric field at fracture 
sites promises to have clinical application.
* Department of surgery,
University of Calgary,
Calgary, AB.
tDepartment of electrical engineering,
University College of Swansea,
Swansea, Wales.
9. IMMUNOGENICITY OF OSTEOSARCOMA IN
the R at , Indu ced  by M ur in e  Sarcom a  
V irus-M o loney
E. P. Urovitz, F. Longer, A. E. Gross, 
A. A. Czitrom and S. K. Stylianos
The immunogenicity of a viral induced rat 
osteosarcoma was studied by the lymphocyte 
microcytotoxicity test. Intratibial injection of 
murine sarcoma virus-Moloney (MSV-M) 
resulted in the development of palpable 
tumours at the injection site, which histo- 
pathologically appeared as osteosarcomas. 
In 73% of animals these tumours pro­
gressed and metastasized to lungs. Lympho­
cytes from these “progressor” animals dem­
onstrated an ability to kill osteosarcoma 
cells in vitro (as quantitated in the micro­
cytotoxicity test) while serum from these 
animals abrogated or blocked the cell- 
mediated cytotoxicity. In the remaining an­
imals the tumours either failed to develop 
or regressed spontaneously. Lymphocytes 
from these “regressor” animals also dem­
onstrated cytolytic activity against osteo-
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sarcoma cells in vitro, but serum failed to 
block the lymphocyte-mediated cytolysis. 
Both regressor and progressor groups dem­
onstrated humoral cytotoxic antibodies to 
tumour antigen on the basis of the ability 
of their serum to kill tumour cells in vitro.
Department of surgery,
Mount Sinai Hospital and University of Toronto, 
Toronto, ON.
10. Interface Between Bone and 
Polymethylmethacrylate U nder 
Load-bearing
/ .  Miller,* D. Burke* and J. W. Stachiewiczf
The increased awareness by physicians of 
loosening or breaking of the components of 
total joint arthroplasty has emphasized the 
need for experimental studies on the inter­
face between the implants and host bone. 
A suitable model was designed for labora­
tory animals to serve as a vehicle for ex­
amining this interface. The model consisted 
of the replacement of a 1.9-cm segment of 
the midshaft of the dog’s femur with a 
metallic intramedullary device. The device 
was cemented into place with polymethyl­
methacrylate. After varying periods of full 
weight-bearing, the bone and implant were 
recovered and histologic thin sections ob­
tained by a technique that preserved the 
surgical polymer.
There were two impressive findings. First, 
blood left on the endosteal surface of the 
bone at the time of the operative procedure 
weakened the bone-cement interface and 
may have contributed to failure. Gaps of 
500 to 1000 p,, filled with blood, were 
seen, in contrast to very thin gaps where 
the bone was prepared by scrupulous clean­
ing before insertion of the polymer. Second, 
cracks appeared in the surgical polymer, in 
a radial fashion, running from the metallic 
implant to the bone-cement interface. These 
were often multiple, occasionally huge, and 
probably were the product of “hoop stress” 
—  that is, tensile forces developing in the 
cement as a result of shrinkage of the 
methacrylate around an unyielding metallic 
core. Calculations indicated that this hoop 
stress can be large enough to exceed the 
tensile strength of the polymer.
♦Department of surgery,
Montreal General Hospital,
Montreal, PQ.
^Department of mechanical engineering,
McGill University,
Montreal, PQ.
11. Method of Hemagglutination for 
the Study of
Collagen-Glycosaminoglycan
Interactions
L. B. Conochie, J. E. Scott, W. P. Faulk 
and A. Bailey
It has been postulated that the func­
tion of various connective tissues in the body 
is related to differences in their mole­
cular composition and internal architecture. 
The interaction of collagen and glycosami- 
noglycans in articular cartilage may be im­
portant in determining its structure. Changes 
in this interaction may have a bearing on 
the susceptibility of articular cartilage to 
undergo changes related to age and wear- 
and-tear.
A simple method of hemagglutination, 
originally designed to detect and measure 
antibody can also monitor collagen-glyco- 
saminoglycan and collagen-proteoglycan in­
teraction in vitro under physiologic condi­
tions of pH and ionic strength.
Tanned sheep erythrocytes coated with 
soluble collagen are agglutinated in the 
presence of certain connective-tissue poly­
saccharides. The “strength” of the collagen- 
glycosaminoglycan interaction is assessed by 
serial dilution of the glycosaminoglycan so­
lution until the end point of agglutination 
is achieved.
In this system, chondroitin 4-sulfate and 
dermatan sulfate interacted strongly with 
collagen. Chondroitin 6-sulfate and heparan 
sulfate interacted less strongly, and hyalu- 
ronate and keratan sulfate were extremely 
weak interactors with collagen. This interac­
tion requires that the triple helical native 
collagen molecule be intact, since mild heat 
denaturation of the collagen abolishes the 
interaction. In control experiments, with 
uncoated or albumin-coated erythrocytes, 
there was no agglutination in the presence 
of the connective tissue glycosaminoglycans.
This method of hemagglutination is rapid, 
simple, economical and requires only small 
quantities of purified material.
Department of surgery,
Montreal General Hospital,
Montreal, PQ.
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12. M icrocrystalline Collagen: A n 
Effective H emostatic Agent to
R educe Bone B leeding
E. L. Thrasher, W. H. Harris and
R. H. Cobden
An effective hemostatic agent that will re­
duce bleeding from bony surfaces, yet not 
inhibit osteogenesis is essential in orthopedic 
surgery. Bone bleeding from osteotomy of 
the greater trochanter, iliac-bone-graft donor 
sites, intertrochanteric osteotomies or frac- 
ures, and many other skeletal injuries is an 
important factor in operative and postopera­
tive blood loss. Bone wax, oxidized cellulose 
and thrombin gelatin foam are commonly 
used despite the lack of quantitative data 
confirming their value. Bone wax reduces 
bone bleeding but interferes with osteo­
genesis.
Microcrystalline collagen, a new agent 
extracted from bovine hide corium and pre­
pared as microcrystals (length, < 1 /T), main­
tains the tertiary structure of the collagen 
and thus binds platelets. Its efficacy as a 
hemostatic agent applied to cancellous bone 
was studied in a series of osteotomies of 
the greater trochanter in 53 dogs. Micro­
crystalline collagen reduced blood loss by 
73% compared with control values and was 
appreciably better than other test agents. 
It reduced blood loss without interfering 
with union of the greater trochanter after 
repositioning.
In a series of patients undergoing total 
hip replacement a similar study was carried 
out. Various agents were applied to the 
cancellous bleeding surface of the trochan­
teric osteotomy. Microcrystalline collagen 
reduced bleeding from the test site by 77% 
and did so without interfering with union 
of the greater trochanter.
Department of orthopedic surgery,
Massachusetts General Hospital,
Boston, MA.
13. N atural H istory of the Patient 
with an Infected Total H ip
Replacement
G. A. Hunter
Review of the natural history of 127 pa­
tients with deep infection after total hip 
replacement revealed that 19 died after the
insertion or excision of the prosthesis. No 
patient died who had a successful implant 
in the appropriate position under a dry 
wound.
Of the patients still living only 17 re­
tained their hip implant in position without 
further wound complications. The remain­
ing patients had their hip implants excised; 
most had dry wounds.
Poor management, despite early recogni­
tion of the infection resulted in a high rate 
of excision of the hip prosthesis.
The results of this survey indicate that a 
second total hip prosthesis should not be 
inserted following deep infection of the 
first implant.
Important considerations are the dif­
ficulties of distinguishing between a positive 
wound culture and clinical infection of the 
wound in arthroplasty of the hip, the bac- 
teriologic aspects of deep infections with 
reference to the use of prophylactic anti­
biotics, and the dangers of metastatic in­
fection in the postoperative period.
Division of surgery,
St. Michael’s Hospital,
Toronto, ON.
14. Pattern of Cortical Bone Loss in
Experim ental D isuse Osteoporosis
H. K. Uhthoff, C. Palmer and Z. F. Jaworski
The effect of disuse on the humerus, radius, 
ulna and third metacarpal was studied in 
eight adult dogs over a period of 2 to 24 
weeks. The dogs were immobilized in a 
shoulder spica; no surgical trauma was in­
troduced.
Radiologic and histologic measurements 
suggest that bone is not lost gradually, but 
in a phasic pattern. Early negative bone 
balance was followed by positive balance at 
12 weeks, which in turn was followed by 
a second, more-pronounced, negative bal­
ance. Measurement of the contribution 
of the periosteal, endosteal and haver- 
sian envelopes to bone loss demon­
strated an impressive periosteal bone loss. 
At 24 weeks all cortices had regained a 
normal density. Any study on the prevention 
or treatment of disuse osteoporosis should 
consider the phasic behaviour of bone loss 
and the contribution of the three envelopes
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to it, as well as the individual behaviour of 
each bone.
Department of surgery,
Ottawa General Hospital,
Ottawa, ON.
15. Permanent Deformation of Bone: 
An Experimental Model in the Dog
C. F. Moseley, V. H. Frankel,
A. H. Burstein and K. G. Heiple
Study of two cases of traumatic bending of 
long bones without evidence of fracture has 
demonstrated, at follow-up, new bone forma­
tion particularly on the concave aspect; in 
one case an onion-skin appearance was 
noted.
An animal model was developed to study, 
in vivo, the nature of, and the response of 
bone to, plastic deformation.
An instrument applying a four-point 
bending load to the canine fibula during a 
sterile procedure was designed so that the 
load-deformation curve could be monitored 
during application of the load. One fibula 
was subjected to loading into the plastic 
region. This was demonstrated by the shape 
of the load-deformation curve and by the 
visual, palpable, and radiologic evidence of 
residual deformation. With that load-de­
formation curve as a reference the other 
fibula was loaded within the elastic region 
only as a control.
Histologic examination and examination 
by ultraviolet light for tetracycline fluores­
cence have failed to demonstrate either the 
morphologic basis of plastic deformation or 
a relation between the remodelling pattern 
and the loading configuration.
Department of biomechanics,
Bingham Building,
Case Western Reserve University,
Cleveland, OH.
16. Prospective Biopsy Study of 
Collagenous Tissues in A rthritic 
Patients for Evidence of Immune 
Complex Deposition
E. Bennett, S. Richer and D. Cooke
Immunoglobulins (IgG, IgA, IgM) and com­
plement components (B1C were previously 
identified in the surface layers of articular 
collagenous tissue biopsies of many patients 
with rheumatoid arthritis (RA), in a location
and form suggesting immune complex forma­
tion. The work was extended as a prospective 
study in which randomly selected arthritic 
patients, all of whom were candidates for re­
constructive surgery, were included. In addi­
tion to cartilage and synovial tissue biopsies, 
the disease state and severity were assessed, 
and immunologic parameters in serum and 
synovial fluid were measured. Data on 208 
patients studied for evidence of immune com­
plex deposition in cartilage have been cor­
related with their diagnostic groups. In pa­
tients with classical RA, more than 92% 
had positive findings. Of those with non­
inflammatory arthritis, findings were posi­
tive in 52% of patients with primary dege­
nerative arthritis and 20% of patients with 
secondary degenerative arthritis. Findings in 
nonarthritic joint biopsies were positive in 
5% . The relatively high incidence of posi­
tive findings in the primary degenerative 
group suggests a potential relation between 
some of these cases and RA, and the po­
tential for immune mechanisms to be in­
volved in pathogenesis. The proportion of 
positive findings in patients with classical RA 
is highly significant when compared with 
the proportion in any other group studied 
(P <0.001). These data support the notion 
that cartilage-localized immune complexes 
in RA play an integral role in chronicity, 
perhaps as a source of persisting antigen.
Department of surgery,
Queen’s University,
Kingston, ON.
17. Resurfacing the Articular
Cartilage of Adult Rabbits by
Multiple Perforations Through 
Subchondral Bone
N. Mitchell and N. Shepard
Articular cartilage was removed from both 
distal femora of adult rabbits. One knee 
served as a control; the other was studied 
after multiple perforations had been made 
through the subchondral bone. Animals 
were sacrificed at intervals up to 1 year and 
cartilage regeneration was studied by light 
and electron microscopy. Initially a car­
tilaginous material, staining heavily with 
safranin 0, filled the holes, and under light 
and electron microscopy this material re­
sembled hyaline cartilage. By 12 months
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resurfacing of the cartilage had occurred, 
though the material lost its hyaline appear­
ance after 8 months and resembled dense 
collagenous tissue. Since this tissue with­
stood wear for 1 year it is speculated that 
it may have some use in temporary resur­
facing of partial cartilage defects.
Orthopaedic research laboratories,
Royal Victoria Hospital,
Montreal, PQ.
18. T he R eversibility of T issue
D ifferentiation  Around Screws
H. K. Uhthoff and J. P. Germain
Previous studies have demonstrated the in­
fluence of mechanical factors on cell dif­
ferentiation — movement around screws 
inserted into compact bones led to bone 
resorption and absence of movement led 
to bone formation. The present study of 12 
adult dogs showed that the morphology and 
function of tissues were also subject to 
mechanical factors. A 4-week-old callus, 
formed under conditions of mechanical neu­
trality, was resorbed when subjected to 
gross movement. On the other hand bone 
resorption resulting from movement around 
the screw ceased and bone formation started 
when the movement was suppressed. The 
results, obtained over an 8-week interval, 
were based on radiologic, histologic and 
fluorescence microscopic examinations. It is 
concluded that not only the differentiation 
of undifferentiated cells but also the state 
of differentiated tissues are influenced by 
local mechanical factors.
Department of surgery,
Ottawa General Hospital,
Ottawa, ON.
19. Scanning E lectron M icroscopy of 
Superficial D efects in Articular 
Cartilage
F. N. Ghadially and A. F. Oryschak
Superficial defects approximately 2 mm in 
diameter were produced by removing a thin 
shaving of cartilage from the medial femoral 
condyle of the rabbit. On the surface of 
these defects many chondrocytes and their 
lacunae, laid bare by this procedure, were 
seen. In specimens collected over the 4- to 
14-day period after operation, the lacunae
became progressivly shallower and their 
margins rounded and obscured. At 3 to 4 
weeks a few, small, thread-like and ribbon­
like structures were seen arising from the 
margins and surface of the defects. With the 
passage of time these became quite promi­
nent, and at 6 months numerous wave-like, 
band-like, rope-like and thread-like forma­
tions were seen coursing over the floor of 
the defects.
Collectively these formations may be re­
ferred to as “flow formations” for they ap­
pear to derive from streaming or flowing 
of cartilage substance, engendered by the 
pressure of load-bearing and shearing 
forces in the joint. The importance and 
ultimate fate of these new structures, re­
vealed by scanning electron microscopy, re­
main to be determined.
Department of pathology,
University Hospital,
Saskatoon, SK.
20. Stress Analysis of the 
Subtrochanteric R egion of the F em ur
G. V. B. Cochran, J. Fielding and 
R. E. Zickel
The subtrochanteric fracture is a clinical 
problem in biomechanics; the relative fre­
quency of nonunion or failure of fixation, 
or both, is related to high mechanical stress. 
Experiments were designed to determine 
subtrochanteric stresses in relation to load­
ing, muscle forces and devices for fracture 
fixation.
The subtrochanteric segment of six intact 
human femora was instrumented in vitro, 
with electrical resistance strain gauges. Sta­
tic loads were applied in three configura­
tions: directly to the femoral head, simulat­
ing two-leg stance; indirectly by apparatus, 
simulating single-leg stance with active ab­
ductors; and indirectly, simulating single-leg 
stance with active abductors and tensor 
fascia lata. Strain measurements during load­
ing were obtained and data converted to 
stress.
For two-leg stance, experimental results 
supported the theoretical stress calculations 
of Koch and of Rybicki and colleagues. 
For single-leg stance, results indicated that 
abductors alone greatly increase subtrochan­
teric strain, up to 600% over two-leg stance.
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Counteracting forces, represented by the 
tensor fascia lata, exert a protective effect, 
limiting stress to acceptable levels. After 
osteotomies, performed to simulate frac­
tures, stresses in the fragments varied with 
type of internal fixation, muscle action and 
loading configuration. The addition of plate 
fixation to intact specimens, representing 
healed fractures, produced substantial “stress 
protection”; bone stress was reduced 30 to 
50% near the plate, and medial-lateral dis­
tribution was altered markedly. In contrast, 
a “Zickel” nail intramedullary device, pro­
vided secure fixation while maintaining more 
physiologic stresses in bone with lower stress 
in the metal.
Alteration in stress patterns caused by 
internal fixation may be important in frac­
ture healing in view of the recognized rela­
tion of mechanical stress to the deposition 
and remodelling of bone. Regarding strength 
of internal fixation, the “device-bone unit”, 
rather than the strength of the device alone, 
is an essential concept.
Department of orthopedic surgery,
St. Luke’s Hospital Centre,
New York, NY.
21. Traumatic Dislocation of the H ip : 
A M icroangiographic, H istologic and 
Radiologic Study
Clive P. Dincan and Sun-Shik Shim
Experimental study of traumatic posterior 
dislocation of the hip in 210 rabbits (60 
mature, 150 immature) revealed that the 
dislocation caused circulatory embarrass­
ment to the femoral head in both adult and 
immature rabbits. The major causative fac­
tor was damage to the extraosseous epi- 
physeometaphyseal vessels of blood supply 
and drainage. Disturbance of the circulation
in immature animals worsened with con­
tinued dislocation reaching a maximum with 
in 24 hours. Recovery did not start unti' 
7 days after dislocation. ^
The perfusion deficit was most severe in- 
immature animals and was maximal in the 
anteromedial portion of the femoral head, 
which was either devoid of perfusion or con­
siderably underperfused within 10 minutes 
of dislocation. Recovery of perfusion within 
the femoral head of immature animals coin­
cided with the development of an extraos­
seous network of epiphyseal blood supply 
and drainage on the posteroinferior femoral 
neck.
Reduction of the dislocated hip in grow­
ing animals damaged the blood supply to 
the femoral head, but early reduction en­
hanced complete recovery of blood supply. 
Reduction 12 hours or longer after the dis­
location did not benefit the rate and extent 
of return of perfusion in the femoral head.
In adult animals, the intraosseous epi- 
physeometaphyseal anastomoses across the 
obliterated growth plate minimized the ef­
fects of damage to the extraosseous epi­
physeal nutrient system.
Aseptic necrosis of the femoral head, 
demonstrated histologically, occurred in 
most animals regardless of skeletal maturity 
or reduction of the hip dislocation. It was 
more common and extensive in immature 
animals.
Abnormal radiologic features within the 
femoral head were seen infrequently be­
tween 5 and 10 weeks after dislocation, 
despite the high incidence of aseptic necrosis, 
but correlated well with the histologic find­
ings.
Department of surgery,
University of British Columbia,
Vancouver, BC.
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DEXON VERSUS CONVENTIONAL SUTURES IN HERNIA REPAIR*
N. BALTAZAR, MDt and D. W. B. JOHNSTON, MD, FRCS[C], FACSt
»n unselected study of 87 inguinal hernior- 
'•hapies was carried out over a 2-year period 
ising polyglycolic acid (Dexon) sutures in 46 
procedures and conventional sutures in the re­
naming 41. Tissue reaction was the same with 
ooth types of suture; however, the incidence of 
recurrence was lower with the use of con­
ventional sutures. This study has not confirmed 
the superiority of Dexon sutures reported in 
other studies.
Une etude portant sur 87 cas non selectionnes 
d’herniorrhaphies inguinales a ete realisee sur 
une periode de 2 ans, alors que des sutures 
d’acide polyglycolique (Dexon) ont ete utilisees 
dans 46 interventions et des sutures conven- 
tionnelles dans les 41 autres operations. La 
reaction tissulaire a ete identique avec les deux 
types de sutures; toutefois, la frequence des 
recidives a ete plus faible avec I’emploi des 
sutures conventionnelles. Cette etude n'a pu 
confirmer la superiorite des sutures Dexon si- 
gnalee dans d'autres etudes.
Polyglycolic acid (Dexon) suture is a re­
latively new absorbable nonprotein material. 
Reports are unanimous in asserting that 
polyglycolic acid is absorbable, has superior 
tensile strength to conventional suture ma­
terial and causes minimal tissue reaction.1' 8 
Postlethwait1' 2 reported that one third of 
the initial strength of polyglycolic acid is 
lost in 7 days and about 80% by 2 weeks. 
Lichtenstein'-1 stated that any suture material 
that loses most of its strength within 2 
weeks should never be used to close sup­
portive structures (aponeurotic tissues of 
the abdominal wall). Rabbits regain less 
than 30% of the original tensile strength at 
the wound site within 2 weeks, and after 2 
months the wound is only about 41% as 
strong as normal tissue,9 Postlethwait2 con­
cluded that longer retention of strength by
*From the department of surgery, Westminster 
Hospital and University of Western Ontario, Lon­
don, ON.
tFormer resident in surgery, Westminster Hos­
pital.
tChief of service — surgery, Westminster Hos­
pital and clinical professor in surgery, University 
of Western Ontario.
Reprint requests to: Dr. D. W. B. Johnston, Chief 
of service — surgery, Westminster Hospital, PO 
Box 5701, London, ON N6A 4S2.
the polyglycolic acid suture would be de­
sirable.
We compared Dexon with conventional 
suture material used for repair of 87 in­
guinal hernias in 76 patients.
M ethods
Numbered envelopes prepared in advance 
were opened by the supervising nurse in 
the operating room. Numbers were chosen 
from a random table and the surgeons used 
the suture material designated. Sutures de­
signated as conventional were Dacron, cot­
ton or silk. Cotton alone was used for all 
layers in a few cases. Conventional sutures 
were used in 41 repairs. Dexon suture was 
used for all layers in 46. In several patients 
undergoing bilateral repair, polyglycolic acid 
sutures were used on one side and conven­
tional sutures were used on the other.
R esults  and D iscussion
Surgeons who were unaware of the su­
ture material used evaluated the wound 
sites at the follow-up examinations. Factors 
adversely affecting wound healing, such as 
obesity, systemic disease and age were not 
taken into consideration in patient selection. 
Patients were followed up and examined 
after a period ranging from 9 to 37 months 
postoperatively. Criteria used in these ex­
aminations were: (a) recurrence, (b) early 
and late complications, and (c) hypertrophy 
of scar tissue.
In all, 80 operative repairs in 69 patients 
were evaluated (follow-up rate, 91% ). Of 
these, 41 were repairs with Dexon and 39 
with conventional sutures. Six recurrences 
were observed in the Dexon group (14.6% ) 
and three in the conventional group (7.7% ), 
indicating no superiority of Dexon su­
ture in the repair of inguinal hernias. In 
fact, there is a low probability that the use 
of nonabsorbable material is more suitable 
in preventing recurrence (x.2 =  0.4, 1 df).
The postoperative complication rate in 
our study was similar in the two groups 
(Table I). With respect to scar tissue forma­
tion, two operative scars in each group were 
more prominent than the rest.
Gallitano and Kondi5 reported that the
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TABLE I —P ostoperative Complication Rate
Complications
Dexon
suture
Conventional
sutures
Slight induration and 
tenderness.................. 1 1
Slight edema and 
ecchymosis................. 4 1
Hematoma (no drainage 
required). . . .............. 0 2
Small subcutaneous 
abscess (drained). . . . 0 1
Total....................... 5 5
rate of incisional hernias with Dexon (used 
in fascial layers) was markedly diminished 
in closures of abdominal incisions. In our 
cases we found a 7% difference in the rate 
of recurrence in inguinal hernia repairs.
C o n c lu sio n s
In spite of the impressive results from 
other reports indicating less tissue reaction 
from polyglycolic acid suture than from 
other suture materials, our study showed no 
substantial difference. We are not convinced 
of the advantages of polyglycolic acid su­
ture for closure of supportive structures and 
therefore we routinely use Ethiflex suture 
(synthetic Teflon-Dacron) for closure of 
the fascial layers in the repair of inguinal 
hernias.
We acknowledge the help of professor Charles 
Rand, Department of epidemiology, faculty of 
medicine, University of Western Ontario.
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U SE  O F T H E R M O G R A P H Y  F O R  T H E  E A R L Y  D IA G N O SIS O F  D E E P  V E IN  
T H R O M BO SIS FO LL O W IN G  H IP O PE R A T IO N S*
AT T KALAMCHI, MB, ChB, FRCS[C]t and LEO J. MAHONEY, BA, MD, MS, FRCS[C]t
Up to 50% of patients suffer from deep vein 
thrombosis (DVT) after major hip surgery. 
Frequently DVT cannot be diagnosed clinically. 
To the present, venography alone has been used 
in these patients, but it is time consuming, 
necessitates an intravenous dye injection and 
is not without complications. Now, however, 
the technique of thermography is available as 
an additional diagnostic aid.
The results of thermography were assessed 
in 24 patients who had recently undergone 
major hip operations and compared with those 
obtained by venography. Thermography did 
identify DVT in the lower leg veins of patients 
with no clinical symptoms, but higher obstruc­
tions were only diagnosed by venography. 
Thermography gave one false-positive result 
later disproven by venography.
Thermography has the advantage of being 
noninvasive and economical; it will become more 
useful when smaller portable systems are 
developed.
Jusqu'a 50% des patients qui subissent une chi- 
rurgie majeure de la hanche, ont a souffrir de 
thrombose veineuse profonde (TVP). Frequem- 
ment, la TVP ne peut etre diagnostiquee clini- 
quement. Jusqu'a present, seule la phlebogra- 
phie a ete utilisee chez ces patients, mais elle 
est fastidieuse, requiere I'injection intraveineuse 
d'un colorant et n'est pas sans complication. 
Toutefois, on peut maintenant avoir recours a la 
thermographie comme technique de diagnostic 
additionnelle.
Les resultats thermographiques ont ete eva- 
lues chez 24 patients qui avaient subi depuis 
peu une intervention chirurgicale majeure de la 
hanche, et ils ont ete compares a ceux obtenus 
par phlebographie. La thermographie a pu iden­
tifier les TVP dans les veines inferieures de la 
jambe chez des patients exempts de symptomes 
cliniques, mais les obstructions superieures n'ont 
pu etre diagnostiquees que par phlebographie.
*From the departments of orthopedic and general 
surgery, St. Michael’s Hospital, University of 
Toronto, Toronto, ON.
tSenior resident in orthopedic surgery, St. 
Michael’s Hospital.
tSenior surgeon, St. Michael’s Hospital, and 
director, thermographic diagnostic services, St. 
Michael’s Hospital. Assistant professor of sur­
gery, University of Toronto.
Reprint requests to: Dr. L. J. Mahoney, 55 
Queen St. E, Ste. 403, Toronto, ON M5E 1R5.
La thermographie a donne un faux resultat posi- 
tif qui a pu, plus tard, etre rejete par phlebo­
graphie.
La thermographie a I'avantage d’etre une tech­
nique non-envahissante et economique; elle de- 
viendra plus utile lorsque des system es porta- 
tifs, moins encombrants auront ete mis au point.
T he proportion of patients in whom deep 
venous thrombosis (DVT) developed after 
hip surgery has been reported to be as high 
as 50% .11 2 Clinical signs may be mislead­
ing or totally absent in many patients. 
Lambie and colleagues,3 who reported on 
111 surgical patients considered to be at 
high risk, found that this complication 
developed in almost half the patients and 
of them, the diagnosis was unsuspected 
clinically in two thirds despite careful scru­
tiny; of those in whom the diagnosis was 
made clinically, the diagnosis was falsely 
positive in a quarter. Orthopedic surgeons 
are unsure of the value of prophylactic anti­
coagulants in patients with proven DVT4' 8 
and there is no proof that such treatment 
actually decreases the incidence of fatal 
pulmonary embolism; neither is there gen­
eral agreement on the anticoagulant drug of 
choice nor the ideal method of administra­
tion.9'13
Because clinical diagnosis is fraught with 
error, there is need for a simple, nonin­
vasive, rapid, readily repeatable, diagnostic 
test to identify DVT in the lower limb for all 
susceptible patients with or without demon­
strable clinical signs. Cooke and Pilcher14 
considered the chemical activity in the limb 
accompanying, and consequent upon, a 
thrombotic episode. They suspected that 
increased heat, though subclinical, could 
be present from an early stage and subse­
quently reported the successful use of ther­
mography to detect subclinical increases of 
limb heat in patients with DVT. This work 
and that of Pilcher2 stimulated our study.
Methods and Patients
Principles of Thermography
Under standard conditions, the thermal 
contours or patterns that exist on exposed 
human skin are determined by applying the
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principle that heat is conducted to the skin 
secondary to variations in blood flow.
The infrared radiation emitted by the 
skin can be collected optically, transformed 
into electrical impulses, amplified and pre­
sented in display form. This is the essence 
of the AGA thermovision system 680 (Aga- 
tronics Ltd., Toronto, Ont.) that we have 
used. It has been described in detail by 
Clark.15 The immense advantage of a tech­
nique as noninvasive as routine photography 
is obvious.
Technique of Screening
Each patient is taken by stretcher to a 
room where the constant ambient tempera­
ture is maintained between 20 and 22°C. The 
patient is exposed (except for a T-binder) 
below the umbilicus for 20 minutes before 
examination. The legs at the ankles are sup­
ported on a bolster under the Achilles 
tendon, which separates the ankles by 15 
cm and keeps the calves clear of the stretcher 
by 5 cm. Twenty minutes is ample time for 
the surface temperature of the leg to 
equilibrate with the ambient temperature.
The time taken to examine one patient 
averages 20 minutes (after 20 minutes of
cooling). As recommended by Cooke and 
Pilcher,14 the thighs and calves are exam­
ined separately. The thermographic patterns 
are recorded in shades of grey (white =  
warm; black =  cool) and coloured iso­
therms on Polaroid film. All thermographic 
examinations have been performed and in­
terpreted by one of us (LJM).
In addition to thermography, venography 
was performed in patients whose first ther­
mogram after hip surgery was performed 
between the 2nd and 4th postoperative day 
and then every 3 or 4 days throughout the 
postoperative period. In such patients one 
satisfactory venogram is obtained after the 
first thermogram, usually between the 3rd 
and 5th postoperative day. Each patient 
is then observed until fully ambulatory 
or until the time of discharge from the 
orthopedic unit. The presence or absence of 
clinical signs of DVT were recorded in all 
patients by one of us (AK).
Patients
In the 12-month period ending July 1974 
we were able to complete this protocol for 
24 patients. The details concerning sex, age 
and surgical procedure are summarized in
TABLE I.—Summary of Results of T hermography and Venogrpahy in 24 Patients*
Patient Age, sex Diagnosis Procedure
Clinical 
signs of D VT Thermogram Venogram
1....................... 57 M F L hip IF — — —
2 ...................... 66 M OA L hip TH — — —
3 ...................... 67 F OA R hip TH — — —
4 ...................... 69 M OA R hip TH — — —
5 ...................... 85 F F R hip IF — — —
6 ...................... 60 M Moore’s P Revised to TH — — —
7 ...................... 61 F OA R hip TH — — —
8 ..................... 70 F Failed TH Revision of TH — — —
9 .................... 70 F OA R hip TH — + +
10.................... 78 F F L hip IF + +
11.................... 77 F F R hip IF + + +
12.................... 49 F F L hip IF + +
13.................... 71 M Nonunion, 
F R hip
TO& BG + + +
14.................... 72 F Nonunion, 
F R hip
Moore’s A + + +
15...................... 69 F AN L hip TH + +
16...................... 67 F F L hip IF + + +
17...................... 77 F F L hip Thompson P — + +
18..................... 56 M F L hip IF + + +
19...................... 75 F OA L hip TH — +
20 ...................... 68 F F L hip IF — +
2 1 .................... 76 F F R hip IF — — +
2 2 ...................... 65 F OA R hip TH — — +
23 ...................... 62 M F R hip IF — + —
24 .................... 53 M OA R hip VO + —
F = fracture, L = left, R = right, OA = osteoarthritis, P = prosthesis, TH = total hip replace­
ment, IF = internal fixation, AN = aseptic necrosis, TO = trochanteric osteotomy, BG = bone graft, 
A = arthroplasty, VO = varus osteotomy.
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Fig. 1.—Positive thermogram —  marked in­
crease in heat in whole limb (white =  warm).
Fig. 2. —Positive venogram indicating extensive 
clot in soleal vein.
Table I; this table also indicates the clinical, 
thermographic and venographic findings in 
all the patients.
R e s u l t s
Eight patients (1 to 8) showed no evid­
ence of DVT on clinical, thermographic or 
venographic examination.
Ten patients (9 to 18) showed evidence 
of DVT on thermographic (Fig. 1) and 
venographic (Fig. 2) examination. Five of 
these (nos. 11, 13, 14, 16 and 18) had 
clinical evidence of DVT at the time of 
the first thermographic examination. In two 
(10 and 15) the clinical evidence was 
equivocal. Three patients (9, 12 and 17) 
had no clinical suggestion of DVT through­
out the postoperative period. In patient no. 
16, a 67-year-old woman with an inter­
trochanteric fracture of the left hip, internal 
fixation with Richards screw and plate was 
done 24 hours after injury. The patient 
developed clinical signs of DVT in the left 
leg on the 3rd postoperative day. Thermo­
gram on the 3rd postoperative day was posi­
tive (Fig. 1). Venogram on the 4th post­
operative day was also positive (Fig. 2).
Two patients showed evidence of DVT 
on venography, but serial thermograms were 
normal. In one (no. 20) the clinical evid­
ence was equivocal. One patient (no. 19) 
had no clinical suggestion of DVT.
In two patients (21 and 22) localized 
high femoral thrombosis in the abnormal 
leg was demonstrated by venography. We 
could not prove by means of thermography, 
the presence of high femoral throm­
bosis on the operative side. The increased 
heat in the upper thigh due to the operation 
obscured the thermogram immediately and 
this heat increase persisted throughout the 
period of observation. There was no clinical 
suggestion of DVT in either patient. In 
patient no. 21, a 76-year-old woman with an 
intertrochanteric fracture of the right hip, 
internal fixation with Richards screw and 
plate was carried out within 24 hours of the 
accident. There were no clinical signs of 
DVT throughout the postoperative period. 
Thermography was normal on the 5th, 8th 
and 12th postoperative days (Fig. 3). Veno­
gram on the 6th postoperative day was 
positive (Fig. 4).
Two patients had normal venograms, but
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Fig. 3.—Thermogram demonstrates increased 
heat in upper thigh around operative site —  a 
constant thermographic finding in postoperative 
hip surgery.
Fig. 4. —Positive venogram indicating presence 
of clot high in femoral vein. There was no clot 
in distal venous system.
definitely positive thermograms. One (no. 
24) had extensive ecchymosis and swelling 
of the lower leg following a femoral osteo­
tomy; clinically it was obvious that the 
thermogram would be of no diagnostic 
value. In the other patient (no. 23) there 
was no clinical suggestion of DVT. How­
ever, we were unable to find a cause for 
this false-positive thermogram.
Among 10 patients with normal veno­
grams there was one false-positive thermo­
gram and among 5 patients with venographic 
evidence of DVT in the calf there were two 
false-negative thermograms.
D iscussion
In the early diagnosis of DVT of the 
lower limb, venography is the only method 
of examination that has an accuracy ap­
proaching 100%. It is time consuming, 
necessitates an intravenous injection of dye 
and is not without complications. Because 
it is noninvasive and because the cost of 
each test is reduced by two thirds, thermo­
graphy has obvious advantages over veno­
graphy.
We did not find thermography as ac­
curate as did Cooke and Pilcher.14 How­
ever, as a screening tool for the examina­
tion of patients with no clinical suggestion 
of DVT, it is useful in the identification of 
thrombosis of the soleal and popliteal 
veins. Because of the heat generated by the 
postoperative reaction after hip operations, 
thermography is of no value in identifying 
patients with localized high femoral throm­
bosis on the side that has been operated on. 
Although none of our patients had veno­
graphic evidence of iliofemoral thrombosis 
on either side, the presence of postoperative 
reaction following hip operations would 
make such a diagnosis difficult, thermogra- 
phically, but would not be a problem in pa­
tients on medical services who had not had 
a recent surgical procedure involving the 
hip or leg. The definitive diagnosis of DVT 
in patients with positive thermograms, as 
well as those with suggestive clinical find­
ings, still must depend on venography.
Although the thermovision system is 
mobile, it is unwieldy. In a hospital where 
patients are accommodated two to a room, 
the logistics of wheeling the apparatus from 
one room to another are practically impos-
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sible. The suitability of a battery-operated, 
completely portable, small unit for this pur­
pose (AGA thermovision 750) is being in­
vestigated.
Conclusion
Following hip operations, thermography 
of the lower limb is a useful screening tech­
nique in diagnosing deep venous throm­
bosis of the soleal and popliteal veins. It is 
economical and noninvasive. The thermo­
vision system used for this study is mobile, 
but unwieldy. It is hoped that a completely 
portable, small unit will soon become avail­
able.
We are indebted to the department of visual 
education, St. Michael’s Hospital, Toronto, for 
their unstinting and cheerful aid in the prepara­
tion of the prints, and to Miss K. Arthurs for 
her patience and help in the preparation of the 
manuscript.
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PROPHYLACTIC ANTIBIOTIC THERAPY AND HEART VALVE
REPLACEMENT*
T. W. AUSTIN, MD, FRCP[C], J. C. COLES, MD, FRCS[C], FACS, R. FINLEY, MD
and B. SCHIEVEN, BA, RT
Patients undergoing cardiac bypass for heart 
valve replacement maintained adequate blood 
concentrations of cloxacillin throughout the dura­
tion of bypass, provided their initial blood con­
centration was in the therapeutic range. Blood 
levels related to the time between the last pre­
operative dose of antibiotic and operation. Maxi­
mal values were achieved if an intraoperative 
bolus of drug was given.
Des patients qui ont subi une derivation car- 
diaque pour le remplacement d’une valvule 
cardiaque ont maintenu des concentrations ade- 
quates de cloxacilline pendant tout le temps ou 
ils ont ete sous derivation, en autant que ies 
concentrations initiales etaient a I'interieur des 
taux therapeutiques. Les taux sanguins etaient 
relies a I’intervale de temps ecoule entre la 
derniere dose d’antibiotique administree avant 
I'operation et (’intervention elle-meme. Les va- 
leurs maximales ont ete obtenues lorsqu'une 
dose massive de medicament a ete donnee pen­
dant I'intervention.
B e c a u se  of the associated mortality,1 in­
fection of valve prostheses remains of major 
concern to the cardiovascular surgeon. Cur­
rently, patients undergoing heart valve re­
placement receive prophylactic antibiotic 
therapy in the intraoperative and early post­
operative period. Although the benefits of 
such a practice are questionable, the cur­
rent low rate of early postoperative valvu­
litis- makes it unlikely that a definitive 
study of risks v. benefits would, or could, be 
undertaken.
Current concern, we believe, should be 
directed to the appropriateness of antibiotic 
used, judged by the data available on or­
ganisms causing prosthetic valvulitis and 
their corresponding antimicrobial sensitivity. 
Further, the optimal timing and duration 
of such therapy as well as the optimal drug 
dosage warrant consideration. The latter is 
of importance since data .are conflicting. 
One study indicated that despite the
*From the departments of surgery and medicine, 
Victoria Hospital, London, ON.
Reprint requests to: Dr. T. W. Austin, Infectious 
disease consultant, Victoria Hospital, 391 South 
St., London, ON N6A 4G5.
agent used, cardiac bypass was asso­
ciated with a precipitous drop in blood 
antibiotic concentrations to subinhibitory 
values.3 A second study suggested that pro­
vided prepump values were satisfactory such 
a phenomenon did not occur.4 Our study 
attempts to clarify this controversy.
M a t e r ia l s  an d  M et h o d s
Twelve adult patients (seven women, five 
men) undergoing single valve replacement 
(nine aortic, three mitral) in late 1974 and 
early 1975 were studied. The average age 
was 58 years (range, 16 to 76 yr). In all 
cases the preoperative serum creatinine 
concentration was less than 1.5 mg/dl and 
there was no evidence of hepatic dysfunc­
tion as judged by normal values for serum 
bilirubin, alkaline phosphatase, lactic dehy­
drogenase and serum glutamic oxaloacetic 
transaminase concentrations.
Ten patients received ampicillin plus 
cloxacillin, while two, with a history of an 
allergy to penicillin, received lincomycin. 
The dose of each antibiotic in all cases was 
0.5 g every 6 hours. The medication was 
given orally 1 day before operation and 
by intramuscular injection on the day of 
operation. In the later part of the study, 
additional antibiotic was given in standard 
dosage intraoperatively by intravenous bolus 
injection.
The time of the last dose of antibiotic 
prior to the initiation of cardiac bypass, to 
the nearest half-hour, was recorded, as were 
the times at which intraoperative blood 
samples were obtained. These were taken 
on three occasions: just before initiation of 
bypass; 30 minutes later, while on bypass; 
and immediately on completion of bypass. 
All blood samples were taken from the fe­
moral artery line, allowed to clot and then 
spun down. The resultant serum samples 
were stored at — 70°C until assayed.
The volume of blood used in priming the 
pump oxygenator, as well as of any blood 
given intraoperatively, was recorded, as 
were those of other solutions given during 
the operative period.
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Serum cloxacillin levels were determined 
and the minimum inhibitory concentration 
(MIC) and minimum bacteriocidal con­
centration (MBC) estimated. The MIC and 
MBC were ascertained with the aid of a 
nonpenicillinase-producing strain of Staphy­
lococcus aureus (ATCC 25923). The pa­
tient’s serum was serially diluted with anti­
biotic medium no. 3 (Difco Laboratories, 
Detroit, MI). An 18-hour culture of 
S. aureus, grown in beef-heart infusion broth 
(Difco Laboratories), was diluted 1:100 
and 1 drop of this, containing approximately 
2.5 x 10 5 colony-forming units (CFU), 
added to each dilution. Following overnight 
incubation at 37°C the specimens were in­
spected for turbidity, the MIC of greatest 
dilution showing none. All dilutions were 
subcultured on blood agar at 37°C over­
night, the MBC being the greatest dilution 
demonstrating no growth on subculture.
To determine serum cloxacillin concentra­
tions a penicillin-resistant S. aureus (hos­
pital strain) was used. It was prepared in a 
fashion similar to the above but diluted to 
approximately 6.0 x 106 CFU. Of this, 1.5 
ml was added to 150 ml of antibiotic me­
dium no. 11 (Difco Laboratories) in agar, 
the mixture poured into a glass-bottom tray 
(250 mm2) and allowed to cool. Cloxacillin 
standards of known concentration (20.0, 
10.0, 5.0, 2.5, 1.25 yug/ml) were prepared in 
pooled human serum. The known standards 
and unknown patient samples were allowed 
to saturate 6-mm filter paper discs and these 
discs were then firmly pressed onto the test 
plate. The standards were tested in quadru­
plicate and the unknowns in duplicate. In 
all cases the discs were randomly applied. 
After overnight incubation the zone of bac­
terial inhibition around each disc was meas­
ured with Vernier calipers to the nearest 
0.5 mm and the average obtained for each 
sample essayed. The standards were then 
plotted on semilogarithmic paper and the 
unknowns extrapolated from the resultant graph.
Initially, patients received 250 to 500 ml 
of blood in the form of a pump prime with 
the occasional patient receiving an addi­
tional unit of whole blood intraoperatively. 
In the latter part of the study, patients often 
received no blood. An additional 2 to 3 l 
of electrolyte solution and dextrose were
given intraoperatively. The average dura­
tion of cardiac bypass was 114 minutes 
(range, 78 to 161 min).
Results
There was one death in the early post­
operative period, unrelated to infection. 
Among the 11 survivors there was no evid­
ence of infective endocarditis at 3-month 
postoperative follow-up.
The MIC and MBC were determined to 
a maximum of 1:32. Eight of 10 patients 
on ampicillin-cloxacillin prophylaxis had 
adequate concentrations throughout. The 
remaining two, with lower concentrations, 
had received their last preoperative dose of 
antibiotics 9 hours before cardiac bypass. 
Similarly, low concentrations were achieved 
in the two patients with lincomycin prophy­
laxis although one of these had received ad­
ditional drug intraoperatively.
Thus patients who received ampicillin- 
cloxacillin prophylaxis within 4 hours of 
operation had adequate antistaphylococcal 
activity in their serum throughout cardiac 
bypass. Lincomycin prophylaxis gave less 
satisfactory levels; however, the sample num­
ber was small.
The cloxacillin values were more than 
adequate to inhibit the growth of S. aureus, 
cloxacillin-sensitive Staphylococcus alb us, 
Streptococcus pyogenes and Diplococcus 
pneumonia“• 6 throughout the period of 
cardiac bypass provided the initial value was 
within the therapeutic range. If serum cloxa­
cillin concentrations were satisfactory at the 
outset of cardiac bypass they remained so 
throughout the period of the bypass. Blood 
values are directly related to the time in­
terval after the administration of the last 
dose of antibiotic. These data are presented 
in Fig. 1.
Discussion
The value of prophylactic antibiotics in 
surgery is in dispute. Some people believe 
that antibiotics, used in this way, expose 
the patient to the toxic and allergic risks 
inherent in the administration of all anti­
microbials, that they do not lower the rate 
of infection, that the normal flora is eradi­
cated, resistant bacteria proliferate and that
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these new opportunistic pathogens them­
selves cause infection that is even more dif­
ficult to treat. None the less in surgical 
procedures associated with a high rate of 
postoperative infection, the administration 
of an antibiotic chosen for its effectiveness 
against pathogens of importance in that par­
ticular procedure has been associated with 
a substantial reduction in the rate of in­
fection.6-7
For procedures associated with a low in­
fection rate similar information is lacking. 
Goodman and coworkers8 attempted to do 
a prospective study on the protective role 
of antibiotics in cardiac surgery. Two cases 
of potentially preventable D. pneumoniae 
endocarditis occurred in a placebo group 
and resulted in termination of the study 
before any statistically valid conclusion 
could be reached. Nevertheless this study 
makes it difficult to justify a further similar 
examination of this question in patients cur­
rently undergoing heart valve replacement.
Current concern should be to define the 
most appropriate drug, the ideal dosage, 
and the best timing and duration of therapy. 
The choice of ampicillin and cloxacillin at
our centre reflects the importance of gram­
positive cocci, particularly S. aureus, S. epi- 
dermidis and streptococci in causing pros­
thetic valvulitis.1' Lincomycin has a spec­
trum of activity similar to that of cloxacillin 
and is used in patients with a history of 
penicillin allergy.
Our results indicate that the combination 
of ampicillin and cloxacillin achieves satis­
factory concentrations of activity against 
penicillin-sensitive staphylococci even when 
the last dose of drug is given some hours 
before operation. However, in view of the 
prevalence of penicillinase-resistant S. au­
reus in hospitalized patients, blood con­
centrations of cloxacillin alone are of ob­
vious importance. It is apparent that to 
achieve maximal blood concentrations of an 
antibiotic it should be administered as close 
to the time of operation as possible. Indeed 
the two patients with no detectable cloxa­
cillin in their blood stream had received 
no antibiotic for 9 hours before operation. 
These results are in keeping with a recent 
study by Kluge and coworkers4 but differ 
from an earlier study by Benner.3 Benner 
found that, irrespective of prepump anti-
0 2 4  6 8 10 12
TIME IN HOURS
Fig. 1.—Serum cloxacillin concentrations are plotted for each patient at three time periods. “0” 
represents time at which patient received last dose of drug (0.5 g) before operation. Patients with 
highest concentrations received drug shortly before operation. * =  sample taken in recovery room.
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biotic blood concentrations, a precipitous 
decline occurred with the initiation of car­
diac bypass so that concentrations quickly 
became inadequate. Benner did not inves­
tigate the cause of the phenomenon; how­
ever, refinements in cardiac bypass tech­
nique as well as marked reduction in the 
amount of blood used during operation may 
explain this difference.
It is apparent that larger doses of cloxa- 
cillin could safely be used in this group of 
patients. However, it is not clear that this 
would offer any significant advantage. A 
larger dose of ampicillin might extend its 
spectrum of activity to sensitive Escherichia 
coli, and nonpenicillinase-producing Proteus 
spp. Although they are frequent colonizers 
and cause urinary and respiratory tract in­
fections among patients postoperatively, 
these organisms are less important in the 
etiology of valvulitis.1 Lincomycin, although 
based on a small patient sample, does not 
appear to provide adequate blood concentra­
tions in the dosage used.
Most prophylactic regimens for open- 
heart surgery are initiated in the 24 hours 
before operation and continued for a vari­
able length of time postoperatively. Re­
stricting prophylaxis to the immediate pre­
operative period attempts to avoid the 
rapid change in endogenous microflora that 
such therapy causes. This period might be 
shortened further because the penicillins are 
rapidly cleared from the blood stream and 
interstitial concentrations lag behind those 
of the serum by 1 to 2 hours.10
Experimental data from Burke’s study11 
indicate that prophylaxis is most effective 
around the time of contamination. If the 
operative period is when major contamina­
tion occurs, as Kluge and colleagues12 sug­
gest, then this is a crucial time for intensive 
prophylaxis. We therefore believe that the 
addition of antibiotics intraoperatively is a 
useful adjunct to heart valve replacement 
surgery. How long such prophylaxis should 
continue after operation in unclear. Pro­
longed antimicrobial therapy is associated 
with side effects including overgrowth by 
resistant microorganisms, diarrhea, drug
rashes, drug fever and superinfection. We 
therefore discontinue such treatment once 
the patient’s chest tubes and indwelling 
catheters are removed, usually about the 4th 
postoperative day. With this approach our 
incidence of postoperative valvulitis over the 
past year has been less than 1 %.
Our data indicate that, with current tech­
niques, provided cloxacillin blood concen­
trations are adequate at the onset of cardiac 
bypass, they remain so throughout the opera­
tive period. There appear to be no major 
advantages to increasing the dose of cloxa­
cillin above 0.5 g although this could safe­
ly be done. Based on the findings in a 
small number of patients, a 0.5-g dose 
of lincomycin provides suboptimal therapy 
for the eradication of S. aureus.
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DIFFUSE CAVERNOUS HEMANGIOMA OF THE SPLEEN
G. C. EJECKAM, MB, BS*
Diffuse hemangioma of the spleen occurred in 
a 59-year-old man. The presenting features were 
a dull ache and heaviness in the left upper 
quadrant for 3 weeks, severe left-sided pain 
and fever immediately before hospitalization, and 
a tender mass in the left upper quadrant. The 
condition was diagnosed at laparotomy; splenec­
tomy was performed. In this case intrahemangio- 
matous hemorrhage had occurred, but not rup­
ture of the spleen, which is a potentially lethal 
complication. Other complications of diffuse 
splenic hemangioma are thrombosis, infarction, 
infection with abscess formation, and partial cal­
cification of the vascular spaces. The condition 
is rare; only 56 cases have been reported.
Un hemangiome diffus de la rate est apparu 
chez un homme de 59 ans. Les symptomes com- 
prenaient une douleur diffuse et une lourdeur 
presentes depuis 3 semaines dans le quadrant 
superieur gauche, une douleur severe du cote 
gauche et de la fievre juste avant I'hospitalisa- 
tion, et une masse sensible dans le quadrant 
superieur gauche. Le diagnostic a ete pose a la 
laparotomie: une splenectomie a ete effectuee. 
Dans le present cas, une hemorragie hemangio- 
mateuse est survenue sans qu'il y ait toutefois 
rupture de la rate, cette complication pouvant 
etre mortelle. Les autres complications de I'he- 
mangiome diffus de la rate sont la thrombose, 
I'infarctus, I'infection avec formation d’abces, et 
une calcification partielle des espaces vasculai- 
res. Cette affection est rare: seulement 56 cas 
ont ete signales jusqu'a maintenant.
D if f u s e  hemangioma of spleen is a rare 
condition; by 1961 only 56 cases had 
been reported in the world literature.1 Diag­
nosis remains a problem and occasionally 
exploratory laporotomy is required. This 
case report illustrates some of the features 
of the condition.
Case R epo r t
A 59-year-old man was admitted to hospital 
with a 3-week history of dull ache and heavi­
ness in the left upper quadrant. Two days be-
* Resident, department of pathology, faculty of 
medicine, University of Ottawa, and department 
of laboratory medicine, Ottawa General Hospital, 
Ottawa, ON.
Reprint requests to: Dr. G. C. Ejeckam, Depart­
ment of pathology, Ottawa General Hospital, 43 
Bruyere St., Ottawa, ON KIN 5C8.
fore admission he experienced a sharp severe 
pain on the same side and became febrile. 
There were no urinary symptoms or change of 
bowel habit and his appetite remained un­
changed. Physical examination revealed a ten­
der mass in the left upper quadrant; neither 
jaundice nor generalized lymphadenopathy 
were noted. The provisional diagnosis was 
between malignant lymphoma and carcinoma 
of colon. Results of barium enema examina­
tion were normal. Exploratory laparotomy was 
performed.
The spleen was found to be enlarged and 
was removed. It weighed 530 g and measured 
15 x 9 x 5 cm. The capsule showed patchy 
fibrous thickening. Splenic tissue had been al­
most completely replaced by multiloculated 
hemorrhagic cysts (Fig. 1).
Microscopy revealed the features of diffuse 
cavernous hemangioma (Fig. 2 ). The vascular 
channels were lined by swollen or flat endo­
thelial cells, and the parenchyma manifested 
hemorrhage, with organization, and calcium de­
position with giant-cell reaction (Fig. 3). Iron 
and calcium stains were strongly positive.
D iscussion
Virchow2 recognized four types of splenic 
hemangiomas: hemangioma simplex, caver­
nous hemangioma, hemangioma telangiec- 
toides and angioblastoma. The hemangioma 
in the present case had elements of heman­
gioma simplex and cavernous hemangioma. 
Cavernous hemangiomas are uncommon in
Fig. 1.—Section through spleen showing multi­
loculated hemorrhagic cystic spaces, with blood 
clots within spaces. Note area of intact splenic 
parenchyma on left.
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Fig. 2.—Features of cavernous hemangioma, with some capillary vascular formation. Fibrous 
elements are increased in intervascular areas (hematoxylin and eosin, reduced by 15% from x 150).
Fig. 3.—Diffuse hemorrhage and organization. Note Gandy-Gamna bodies in parenchyma (hema­
toxylin and eosin, reduced by 15% from x 60).
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the spleen: they may be asymptomatic 
throughout life and only incidentally dis­
covered at autopsy. 3 5 Occasionally splenic 
enlargement is found during routine phys­
ical examination or symptoms related to 
splenomegaly are noted.6' 7 An enlarging 
left upper abdominal mass, persistent or in­
termittent pain, vomiting, dyspnea and pal­
pitations, all, either individually or in com­
bination, may indicate a splenic heman­
gioma. In the patient whose case is re­
ported herein, the sharp pain was probably 
caused by hemorrhage into the angiomatous 
spaces with sudden tension of the splenic 
capsule.
Rupture of the spleen is a complication 
of intrahemangiomatous hemorrhage. This 
is fatal if unrecognized. The other chief 
complications are thrombus formation, in­
farction, infection with abscess formation 
and partial calcification of vascular spaces. 
The combination of focal fibrous scars con­
taining deposits of hemosiderin and calcium 
—  Gandy-Gamna bodies —  are indicative 
of recurrent hemorrhages, organization of 
blood in some of the hemangiomatous 
spaces.
In the present case there was evidence of 
a mild normocytic, normochromic anemia 
but there were no target cells, schistocytes, 
neutrophilia or thrombocytosis, indicating 
autosplenectomy. Also absent were severe 
anemia and consumption coagulopathy, 
which have been described as presenting 
clinical features. 8' 10
Splenic hemangiomas are benign tumours. 
Reports of malignant transformation of 
splenic hemangiomas11 14  must be as­
sessed critically, as adequate documentation 
is still lacking.
I thank Dr. E. Liepa, department of pathology, 
Ottawa Civic Hospital, for his help and permis­
sion to study the case files; Dr. G. Tolnai, de­
partment of pathology, Ottawa General Hospital, 
for his help and encouragement; Dr. D. Hill, 
director of laboratory medicine, Ottawa General 
Hospital, for his critical review; and the librarian 
and secretaries, department of pathology, Ottawa 
General Hospital, for their help in preparing this 
manuscript.
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CONSERVATIVE MANAGEMENT OF EXTRAUTERINE PREGNANCY*
MICHAEL B. QUANE, MAO, FRCOG
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An abdominal pregnancy in a 28-year-old nul- 
liparous woman with a fertility problem was 
treated conservatively. The clinical antenatal 
course was unremarkable. A healthy 2000-g in­
fant was delivered at term by laparotomy. The 
placenta was removed at the same time. Three 
years later the patient had a ruptured tubal preg­
nancy which was treated by salpingectomy. The 
literature on extrauterine pregnancy is reviewed 
briefly.
Line grossesse abdominale survenant chez une 
nullipare de 28 ans qui presentait un probleme 
de fertilite, a re?u un traitement conservateur. 
L'evolution clinique prenatale a ete sans his- 
toire. Un enfant de 2000 g en bonne sante a 
ete accouche par laparotomie. Le placenta 
a egalement ete retire. Trois annees plus tard, 
la patiente a presente une grossesse tubaire 
avec rupture qui a ete traitee par salpingecto- 
mie. La litterature sur la grossesse extra­
uterine est revue brievement.
The  literature on the subject of extrauterine 
pregnancy is pessimistic; maternal morbidity 
is significant and fetal death rate is high. 
Bright and Maser1 could find only 12 au­
thentic case reports of abdominal pregnancy 
with maternal and infant survival to 1961. 
It is therefore understandable that few at­
tempts have been made to treat cases diag­
nosed in the first trimester conservatively. 
Is conservative management of such cases 
ever justifiable?
Case R eport
The Clinical Course
A 28-year-old nulliparous woman, with an 
unremarkable past history, presented with a 
fertility problem; she had been trying to be­
come pregnant for 2 years, without success. 
The physical findings, including a pelvic ex­
amination under anesthesia, were unremark­
able.
Carbon dioxide insufflation was carried out; 
the gas passed with no demonstrable peris­
talsis. An endometrical biopsy was done; the 
curettings showed features consistent with
*From the department of obstetrics, Prince Rupert 
Regional Hospital, Prince Rupert, BC.
Reprint requests to: Dr. M. B. Quane, 204 — 
1288 Summit Ave., Prince Rupert, BC V8I 2A5.
tubercular endometritis, but tubercle bacilli 
were not identified. The patient was treated 
with antituberculous drugs for 14 months, 
after which endometrial biopsy and culture 
were repeated and reported as normal.
The patient presented 5 months later with a 
history of secondary amenorrhea for 6Vi 
weeks, intermittent nausea, slight urinary fre­
quency and breast tenderness; she suspected 
she was pregnant. Results of a complete gen­
eral examination were normal.
The patient returned for follow-up 1 month 
later with a 10-week history of amenorrhea, 
slight backache, left lower quadrant discom­
fort and slight bleeding for 12 hours.
Pelvic examination under anesthesia re­
vealed a soft and slightly enlarged uterus and 
a tangerine-sized solid mass of limited 
mobility in the region of the left appendage. 
The result of the urine pregnancy test was 
positive and extrauterine pregnancy was sus­
pected.
The patient and her husband wished the 
pregnancy to continue despite the risks, 
which were fully explained to them. 
Probable genital tract turberculosis and a 4- 
year history of infertility encouraged me to 
agree with this decision; the chance for a 
normal pregnancy was considered remote.
The patient remained in hospital for 9 
weeks. In that time she remained well except 
for a 2-week period of intermittent abdominal 
discomfort associated with swelling of the 
pregnancy mass to twice its usual size. The 
swelling was resonant and soft; it subsided 
following the passage of flatus and there was 
no associated constipation, vomiting or pain.
At 19 weeks the patient was discharged 
and followed on a weekly basis. The mass 
continued to grow, but the patient complained 
only of occasional abdominal discomfort. The 
margins of the mass seemed to be irregular. 
Initially it filled the left lower quad­
rant; subsequently it crossed the midline at 
the umbilicus, and became more symmetrical. 
Fetal movements were first felt by the pa­
tient at 14 weeks, and the fetal heart was 
first heard at 29 weeks. The head engaged in 
the pelvic brim at 34 weeks.
The Delivery
The patient was admitted to hospital for 
elective laparotomy at term. Immediately be­
fore laparotomy a blood transfusion was be­
gun and the patient was examined vaginally.
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The uterus could not be outlined; the cervix 
was not dilated and the fetal head, which was 
in the pelvic cavity, had no direct relation to 
the cervix, which lay to the front and slightly 
to the left of the head.
The abdomen was opened through a ver­
tical, subumbilical, midline incision. The fetus 
lay longitudinally in the peritoneal cavity; an 
incomplete sac had formed around it; the 
pouch of Douglas was inferior; the posterior 
leaf of the left broad ligament and the placenta 
were anterior. The placenta had developed 
normally on the posterior leaf of the left 
broad ligament. The broad ligament itself had 
been drawn high up into the peritoneal cavity, 
and in this way formed much of the anterior 
and left anterolateral wall of the sac. Su­
periorly, the wall of the sac was formed by 
the transverse colon and mesentery. The pos­
terior parietal peritoneum formed the posterior 
wall of the sac. The sac was formed on the 
right side anterolaterally in part by adhesions 
between the omentum and the small intestine. 
The uterus lay above and slightly to the left 
of the symphysis pubis. The right appendage 
was free; the left appendage formed a part of 
the mass including the broad ligament and 
placenta.
The Baby
The infant was removed with ease by 
dividing the loose adhesions between the small 
intestine and the omentum on the right side. 
The baby (a normally developed 2000-g fe­
male) breathed spontaneously and remained 
well.
The Placenta
A decision was made to remove the pla­
centa. This was done by approaching it from 
the attachment between the transverse colon 
and its mesentery, and the amniotic mem­
branes. The membranes were peeled off easily 
with care taken to avoid damage to the mid­
dle colic artery. Brisk bleeding was encountered 
in separating the placenta from its main ma­
ternal blood supply in the left broad ligament. 
At this stage, the rate of blood transfusion 
was increased by the application of positive 
pressure. Hemostasis was secured by removing 
the posterior portion of the left broad liga­
ment and the left fallopian tube and ovary. 
The abdomen was closed without drainage. 
The patient’s general condition remained good 
throughout. The estimated blood loss was 21; 
5 units of blood had been transfused. The 
mother’s convalescence was uneventful; the 
mother and baby were discharged on the 
18th day.
Subsequent Course
Three years later, while on vacation, the 
patient complained of vomiting, intermittent 
abdominal pain relieved by frequent bowel 
action, breast tenderness and amenorrhea for 
5 weeks following a regular 26-day cycle. Non­
specific gastrointestinal upset was diagnosed 
and the patient was treated conservatively. 
Her symptoms did not subside completely and 
continued for 8 days, but she was well enough 
to continue her vacation.
The abdominal pain recurred 4 days later 
and was associated with slight vaginal bleed­
ing and a recurring feeling of faintness. On 
admission to hospital, a pelvic examination 
was done and a right-sided appendage mass, 
about the size of a hen’s egg, was palpated. 
A blood transfusion was started and the ab­
domen was opened; approximately 1.5 l 
of free blood was found in the peritoneal 
cavity. A rupturing pregnancy was noted at 
the fimbriated end of the right tube; a right 
salpingectomy was performed. At the time 
of surgery, the previous operation site was 
inspected and found to be healthy and clear 
of adhesions. The convalescence was unevent­
ful, and the patient was discharged from hos­
pital 10 days later in good health.
Postscript
In the 7 years that have elapsed since the 
birth of this baby, the child has remained 
perfectly well. At the time of writing, the 
child was considered to be physically normal 
and of above-average intelligence. The pelvic 
findings in the mother reverted to normal. 
The endometrium has been biopsied and cul­
tured twice in this time with negative re­
sults. The mother’s general health has re­
mained excellent.
D iscussion
Frequency of Extrauterine Pregnancy
It is difficult to obtain meaningful com­
parative data on the frequency of abdominal 
pregnancy because the statistics are reported 
by a variety of authors in different ways. 
Beecham and Beecham2 reported the fre­
quency of abdominal pregnancy as 1 in 
2081 births, while Eastman and Heilman3 
reported 1 in 15 000 deliveries and Grech4 
recorded a hospital rate of 1 in 1814 ad­
missions.
Discrepancies occur for three reasons. 
First, abdominal pregnancy seems to be most
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often recorded in countries where medical 
services are underdeveloped and where 
records are sometimes inadequate. Second, 
in relation to advanced abdominal preg­
nancy, cases are recorded under two head­
ings: abdominal pregnancy and extrauterine 
gestation. These terms have been applied 
loosely; for example, Naidu and Reddy0 
recorded eight cases of advanced extraute­
rine gestation, in which two of the preg­
nancies had remained confined to one horn 
of a bicornual uterus. Third, the term “ad­
vanced” has been used by authors in dif­
ferent ways: Clark and Bourke6 took it to 
mean that the gestation period was over 12 
weeks; Mitra,7 over 51/2 months; and King* 
used the term for gestations longer than 28 
weeks.
Terminating Pregnancy
Current thinking tells us that the intra­
abdominal pregnancy should be terminated 
as soon as it is diagnosed, because of the 
low fetal salvage rate and the high maternal 
mortality and morbidity in late pregnancy. 
Ziel9 reported a maternal mortality rate of 
from 14 to 32% and a fetal mortality ap­
proaching 100%. The chance of a baby 
developing normally appeared to be about 
10%.
Removal of the Placenta
It is widely believed that total removal 
of the placenta lessens morbidity, even 
though there is an associated high rate 
of maternal mortality, secondary to hemor­
rhage.
Most surgeons believe that all loose mem­
branes of the sac should be removed, and 
the cord, if left in situ, not ligated, because 
of the possible subsequent development of 
chorioamniotic cysts. If the placenta is 
left in situ, absorption may occur as early 
as 4 months and as late as 6 years after 
delivery.
Primary Peritoneal Implantation
Most cases of abdominal pregnancy are 
secondary to peritoneal implantation of the 
ovum. Though it is extremely doubtful if 
primary peritoneal implantation ever occurs, 
Miller10 recorded a 23-day pregnancy im­
planted in the peritoneum below the right 
uterosacral ligament; he was convinced that 
this was a case of primary implantation.
Extra- and Intrauterine Pregnancy
Combined abdominal and intrauterine 
pregnancy has been documented by Sehdev 
and Sehdev;11 a liveborn male infant (weight, 
1456 g) with no apparent congenital abnor­
malities was delivered by cesarian section 
and at the same time an 896-g male still­
born with undescended testicles and a right 
club foot was removed surgically from the
abdomen.
■»
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B O O K  R E V I E W S
D’ABREAU’S PRACTICE OF CARDIOTHO- 
RACIC SURGERY. 4th ed. J. Leigh Collis, 
D. B. Clarke and R. Abbey Smith. 710 pp.
III list. Edward Arnold (Publishers) Ltd., 
London; The Macmillan Company of Can­
ada Limited, Toronto, 1976. $93.00.
This edition of professor d’Abreau’s text­
book is again a useful description based on 
experience in a single practice.
The section on pulmonary surgery is ex­
cellent; the descriptions are practical and 
oriented to patient management. The section 
on valvular procedures, based on the author’s 
experience, is informative and practical; on 
the other hand, the chapters on congenital 
heart disease, coronary artery disease and pace­
makers, which reflect an admitted limited ex­
perience, are inadequate. The book ends with 
good sections on thoracic injuries, the eso­
phagus and the diaphragm.
Although the sections on cardiac surgery 
have limitations, those on thoracic surgery 
are welcome. The single-author approach 
avoids some of the errors, contradictions, 
omissions or duplications of multiauthor text­
books.
M. Brais
Department of cardiovascular and thoracic surgery, 
Ottawa Civic Hospital,
Ottawa, ON.
ADVANCES IN CANCER SURGERY. 
Edited by John S. Najarian and John P. 
Delaney. 608 pp. lllust. Stratton Intercon­
tinental Medical Book Corporation, New 
York; Longman Canada Limited, Toronto, 
1976. $28.50.
This volume was developed from a continuing 
education course sponsored by the department 
of surgery, University of Minnesota. It con­
tains several groups of papers of varying qual­
ity. The first group deals with principles of 
cancer therapy including environmental car­
cinogens, virology, cancer chemotherapy and 
immunotherapy, radiotherapy and factors in­
fluencing metastases. Subsequent sections are 
organized on a systemic or regional basis. 
These include discussions on various aspects 
of the lymphomas, head and neck tumours, 
cutaneous malignancies, intrathoracic tumours, 
sarcomas and breast cancer. The final section 
covers a variety of topics including groin and 
axillary dissection, pediatric malignancies, in- 
trascapulothoracic and hemipelvectomy ampu­
tations, testicular and ovarian masses. Most 
sections also contain a panel discussion, though
on three occasions the discussion concerns pa­
pers that are located in later sections of the 
book. Gastrointestinal, biliary, pancreatic and 
hepatic malignancies are not discussed because 
they were considered at an earlier course; sur­
gical technique is not emphasized, though some 
authors provide a few personal tips.
The book will not be attractive to the per­
sonal libraries of most Canadian surgeons, as 
most of the subjects are more throroughly 
covered in standard texts and, of course, ab­
dominal malignancies are omitted entirely. 
Moreover, the publication of oral presenta­
tions requires rigorous editing to achieve the 
desirable degree of brevity.
J. E. D evitt
Director, Continuing medical education, 
University of Ottawa,
Ottawa, ON.
ADVANCES IN NEPHROLOGY. Volume 
5. From the Necker Hospital. Edited by 
Jean Hamburger, Jean Crosnier and Morton 
H. Maxwell. 364 pp. lllust. Year Book 
Medical Publishers, Inc., Chicago, 1975. 
$29.50.
This excellent review of advances in nephrology 
is published annually from the Necker Hos­
pital in Paris, France, under the auspices of 
professor Hamburger. The nephrology group 
of Necker Hospital has a wealth of both 
clinical and laboratory experience in all areas 
of nephrology; they are especially knowledgea­
ble in the field of renal transplantation.
This year’s volume concentrates on glome­
rular disease and renal transplantation. All of 
the chapters are concisely and clearly written; 
they will be easily understood by clinicians 
working in these fields. The chapter on recent 
advances in the understanding of rejection by 
professor Hamburger is outstanding, and is 
highly recommended to anyone seeking a cur­
rent view of this phenomenon.
G eorge A. D eV eber
Toronto Western Hospital,
Toronto, ON.
CHEMOTHERAPY OF UROGENITAL TU­
MORS. Gerald P. Murphy and Arnold Mit- 
telman. 268 pp. lllust. Charles C Thomas, 
Publisher, Springfield, IL, 1975. $24.50.
This book is a monograph in the Bannerstone 
division of American lectures in living 
chemistry. This series was conceived to ad- 
(Continued on page 366)
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vance the newer knowledge of chemical medi­
cine in the cause of clinical practice, and this 
book certainly fulfils that requirement. It joins 
a rapidly growing number of books on cancer 
chemotherapy and oncology, all of which 
attempt to keep practising physicians up- 
to-date in the rapidly changing field.
As noted in the foreword by Dr. Willet 
Whitmore, “among the useful purposes served 
by this volume are the collation and organiza­
tion of the scattered and scant information 
concerning the chemotherapy of urologic neo­
plasms and the indication of the already im­
plemented or proposed means of expanding 
knowledge in this area”. The authors have en­
listed the aid of Dr. Stephen Carter of the 
National Cancer Institute, who has contributed 
three chapters. Specific tumours covered in the 
book include those of the kidney, prostate, 
testicle and bladder, and squamous cell carci­
noma, neuroblastoma, Wilms’ tumour and 
adrenal tumours. There is also a chapter on 
genitourinary sarcomas and other infrequent 
neoplasms. The last chapter, on animal 
models used for experimental chemotherapy of 
genitourinary tract tumours, is a synopsis of 
laboratory research being done in this area and 
adds to the value of the presentation.
This small volume is clearly written, easy 
to read and well illustrated. An excellent re­
view of previous studies, it also fully docu­
ments present efforts and makes recommenda­
tions regarding future areas of research.
I strongly recommend this book to anyone 
who is interested in the chemotherapy of these 
tumours, particularly urologists, general sur­
geons and medical oncologists.
D. J. K l a a s s e n
The Ontario Cancer Foundation,
Ottawa Clinic,
Ottawa, ON.
HAND SURGERY. 2nd ed. J. Edward Flynn.
712 pp. Hlust. The Williams & Wilkins
Company, Baltimore; Burns & MacEachern
Limited, Toronto, 1975. $53.50.
The first edition of Flynn’s textbook on hand 
surgery received wide acceptance. With the 
addition of 21 new contributors to the second 
edition, the value of the textbook should be 
enhanced. Each chapter is a well-written, self- 
contained item by an authority on the subject. 
For this reason it is not necessary to describe 
highlights within the book. The format makes 
for easy subject identification. To keep costs
PRODUCT OF
Upjohn
STEROID
RESEARCH
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low, the print is small and the text is closely 
packed, but once the reader becomes accus­
tomed to this arrangement, it is quite ac­
ceptable.
This book will be a welcome addition to 
the library of the hand surgeon and should be 
placed in all medical libraries as a valuable 
reference source.
R. M. McFarlane
Department of surgery,
Victoria Hospital,
London, ON.
INSTRUCTIONAL COURSE LECTURES. 
Volume XXIV, 1975. American Academy 
of Orthopaedic Surgeons. 328 pp. Illust. The 
C. V. Mosby Company, St. Louis, 1975. 
$26.80.
The American Academy of Orthopaedic Sur­
geons offers each year to the medical com­
munity 120 instructional course lectures over 
a 5-day period. A large number of formal 
papers and audiovisual programs are included. 
This text covers a few of the lectures. There 
is no particular theme and the material is 
selected at random. However, over the years 
they have formed a collective review of cur­
rent orthopedic topics. The material is of in­
terest to all orthopedic surgeons but is aimed 
primarily at residents and young orthopedists.
This year 30 acknowledged experts discussed 
a wide range of topics; among these were 
some of special interest such as biomaterials, 
resistant congenital club foot, peripheral nerve 
suture techniques, traumatic instability of the 
wrist and surgical approaches to intrinsic 
finger muscle dysfunction.
An annual series of lectures followed up by 
a documentation of the better ones in this 
way is a useful educational technique; other 
specialties would do well to emulate this meth­
od of postgraduate education.
L. H. Bartlett
Department of orthopedics,
Lions Gate Hospital,
North Vancouver, BC.
METHOD OF UROLOGY. Arthur W. Wyker, 
Jr. and Jay Y. Gillenwater. 365 pp. Illust. 
The Williams & Wilkins Company, Balti­
more; Burns & MacEachern Limited, 
Toronto, 1975. $17.60.
The authors have tried to provide a volume 
that “fills the gap between the definitive refer­
ence books and the simplified manuals”.
“Method of Urology” is an outgrowth of the 
teaching program at the University of Vir­
ginia.
This book has many worthwhile features: 
it supplies a useful review of recent urologic 
thought, includes a concise, relevant and cur­
rent bibliography at the end of each chapter 
and is written clearly. However, it has some 
drawbacks. First, unrelated topics, classifica­
tions and points of interest are lumped together 
into brief alternately numbered and lettered 
paragraphs; this frequently confuses the is­
sues involved. Second, the authors have tried 
to include many points of view but have fre­
quently failed to draw together and interpret 
the data. Finally, too often the authors have 
mixed anectodal information and scientific 
fact.
Should further editions aim at correcting 
some of the problems, the authors will have 
made a significant contribution to the urologic 
literature. In its present form the book is 
useful; it does accomplish the authors’ stated 
objectives.
POLYPOID LESIONS OF THE GASTROIN­
TESTINAL TRACT. 2nd ed. Claude E. 
Welch and Stephen E. Hedberg. Vol. II in 
Major Problems in Clinical Surgery. 220 pp. 
Illust. W. B. Saunders Company, Philadel­
phia; W. B. Saunders Company Canada 
Limited, Toronto, 1975. $13.90.
This small monograph is another definitive 
work in the series entitled “Major Problems 
in Clinical Surgery”, the second edition of 
the Welch treatise of several years ago. A 
major addition to the second volume of this 
text results from the development of colono­
scopy. Contained within this work is a de­
scription of colonoscopy, detailed as though 
the author were desirous of teaching everyone 
this procedure. Its uses and its abuses are well 
reviewed and the current state of the art is 
well presented.
Definitions of the various types of polypoid 
lesions, once again presented, still defy clarity 
and precision, probably because the lesions 
are not so distinct that they can be easily de­
fined. Polypoid lesions are divided into adeno­
matous, villoglandular, villous, polypoid and 
malignant. An interlocking discussion shifts 
back and forth between the various cate-
B. M. Mount
Department of urology, 
Royal Victoria Hospital, 
Montreal, PQ.
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gories, perhaps related to the changing criteria 
of pathologists and uncertainties regarding the 
malignant potential of the various pathologic 
findings. There is a fairly long discourse on 
the problems of cancer originating in polyps, 
with a good discussion of the literature, and 
a reasonably comprehensive statement of the 
author’s own position on this complicated 
topic.
The book departs from the issue of poly­
poid lesions, per se, by providing recommenda­
tions for the management of colonic polyps. 
These are given by a thoughtful, careful ex­
pert in the field, and are buttressed by an ex­
tensive discussion of operative techniques; 
once again this is probably too detailed for 
those not conversant with the field, and in­
sufficiently detailed for the expert surgeon.
The discussion concerning the remainder 
of the gastrointestinal tract (esophagus through 
small bowel) and the polypoid lesions occurring 
within this segment of the intestinal tract is 
less well done and less thorough than the 
discourse on the colon.
The book contains a good bibliography and 
is a handy reference work; probably it belongs 
in the library of every surgeon who operates 
on the colon.
C. B. M u e l l e r
Department of surgery,
McMaster University,
Hamilton, ON.
STRESS FRACTURES. Michael Devas. 240
pp. Illust. Churchill Livingstone, Edinburgh;
Longman Canada Limited, Toronto, 1975.
$54.00.
Stress fracture is too often not considered in 
the differential diagnosis of diffuse aching 
pain. Dr. Devas has in this short monograph 
collected and categorized this type of injury 
for us.
In the introduction the author describes the 
pathogenesis of this type of injury so common 
to the young and healthy. Signs and symptoms 
are well described with adequate detail; the 
value of these is reinforced by well-reproduced 
radiographs. It is unfortunate that the excellent 
figures are often widely separated from the 
related text. There is at times a trend to re­
dundancy because example cases are described 
and the detail is repeated in the accompanying 
radiograph. The author’s thoughts on cer­
tain types of avascular necrosis being initiated 
by compression-type stress fractures are inter­
esting and worthy of further investigation.
This book brings to light, in a simple and 
organized way, a collective reminder of a
much forgotten injury. It serves to remind the 
reader that the diagnosis of a stress fracture 
must be suspected and made clinically.
M . A. R osm a n
Division of orthopedic surgery,
Montreal Children’s Hospital,
Montreal, PQ.
SURGICAL DISORDERS OF THE PERI­
PHERAL NERVES. 2nd ed. Sir Herbert 
Seddon. 336 pp. Illust. Churchill Living­
stone, Edinburgh; Longman Canada Lim­
ited, Toronto, 1975. $43.25.
Except for a few changes, this second edition 
of Seddon’s monograph appears to be identical 
to the first. In some respects this lack of 
change has led to omissions in the book’s con­
tent. Thus, the recent advances in clinical 
neurophysiology, microsurgical techniques and 
perineural nerve repairs are alluded to in the 
preface, but are not described in the text. Like­
wise, "despite recent developments in the field, 
the chapter on electrical phenomena is un­
changed; intraoperative functional assessment 
at the fascicular level is not referred to. The 
work of Narakas on the surgical management 
of brachial plexus injuries and of Millesi on 
nerve grafts are detailed, but new microsuture 
and microsurgical techniques for nerve repair 
are barely mentioned; the section on operative 
treatment is therefore somewhat out of date.
In spite of its limitations, this book is high­
ly recommended to all concerned with the 
repair of peripheral nerves; it is the most com­
prehensive review on the subject of peripheral 
nerve surgery to date and is an essential com­
panion volume to Sunderland’s book “Nerves 
and Nerve Injuries”.
J. K . T erzis
Department of surgery,
Dalhousie University,
Halifax, NS.
TRANSPLANTATION TODAY. 3. Edited by 
Michael Schlesinger, Rupert E. Billingham 
and Felix T. Rapaport. 992 pp. Illust. Grune 
& Stratton, Inc., New York; Longman Can­
ada Limited, Toronto, 1975. $43.50.
There are few areas in medicine where the 
applied science changes as rapidly as it does 
in the field of transplantation. Several text­
books have been written on transplantation by 
physicians and surgeons over the last 10 years 
and most of them now are of historical interest 
only. It is of importance, therefore, that the 
new information currently published in over 
a dozen immunologic and clinical journals be
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brought together at regular intervals so that 
physicians and medical scientists interested in 
the applied aspects of transplantation can re­
main abreast of the field.
The Transplantation Society (an interna­
tional society embracing both basic scientists 
and clinicians) meets every 2 years. Dr. Ra- 
paport, who is editor of Transplantation Pro­
ceedings, the official journal of the Transplanta­
tion Society, has taken on the task of publish­
ing the proceedings of the international meet­
ing as an updated “textbook” of transplantation 
in the year following the meeting of the so­
ciety. This represents the third such issue. 
Because the contents of this meeting contain 
both invited papers and free communications, 
the content is frequently highly technical and 
of a basic science nature. Nevertheless, of the 
992 pages in this volume, one-third of the 
content is of direct interest to those doing 
clinical transplantation.
The rapid changes occurring in the field of 
histocompatibility make the introductory sym­
posium on histocompatibility immunogenetics 
and the section on the role of transplantation 
antigens in human transplantation and sus­
ceptibility to disease important for the reader 
who wishes to update his knowledge in this 
field.
A special section deals with tolerance or 
enhancement as a solution to the clinical prob­
lems of transplantation. We learn that the 
in-vitro mechanisms elucidated from sophisti­
cated studies may not be of great clinical 
importance and that the real roles for the 
delicate immunoregulatory mechanisms are 
not yet understood.
The correlation of in-vitro immune responses 
with clinical rejection is dealt with in detail. 
It points up the weakness of looking at any 
single part of a complex (immune) response, 
in attempting to explain highly variable clin­
ical courses. In spite of these negative find­
ings, the reader is impressed with the abundant 
scientific information and the potential of 
applied assays in dissecting with greater ac­
curacy the immune response in the transplant 
recipient.
The section on clinical transplantation is a 
follow-up report of 124 long-term transplants 
of 8 to 12 years’ duration. Although gen­
erally, patient survival was considerably less 
in the period preceding 1966, the overall pa­
tient survival was 56% in the related noniden­
tical transplants and 41% in the cadaveric 
transplants. The primary causes of death in 
the long-term survivors were sepsis, late re­
jection and liver failure. Interesting new areas
of endeavour include the transplantation of 
pancreatic islet cells with a resulting subse­
quent correction of the renal lesion in diabetes.
The use of single allele shared skin allo­
grafts for the treatment of burns is reported; 
this is an area of great clinical promise. The 
most significant advance at a clinically applied 
level is in the field of bone-marrow transplan­
tation. Several centres (primarily the Seattle 
group) have demonstrated that bone-marrow 
transplantation is the current treatment of 
severe aplastic anemia.
It is essential, in my opinion, for any 
clinical scientist interested in transplantation 
to have available to him either in his own 
library or through his local medical library 
a copy of “Transplantation Today”, volume 3. 
The information contained in this text is dated 
but is still the most current available.
C. R. St il l e r
Nephrology and transplai '.tion division, 
University Hospital,
London, ON.
VASCULAR SURGERY. Edited by William
H. Edwards. 257 pp. lllust. University Park
Press, Baltimore, 1976. $24.50.
This book on vascular surgery covers a broad 
range of topics. It is easy to read and provides 
lessons from clinical experience by leading 
vascular surgeons on techniques, diagnosis and 
treatment.
The chapter on cerebrovascular insuffi­
ciency is clear and concise; readers will find 
it extremely helpful as a guide for the man­
agement of these diseases.
The book contains illustrative case histories 
of cerebrovascular occlusive disease; of special 
interest are the case presentations of vertebro­
basilar insufficiency and the subclavian steal 
syndrome. Also useful are the many important 
clinical points concerning aortoiliac and peri­
pheral vascular diseases, the comprehensive 
coverage of the management of renovascular 
hypertension and the specific technical details 
of surgery for resection of common aneurysms.
The vascular injuries are well described; 
this section includes both aortic and arterial 
injuries and associated thromboembolism.
General surgeons who are practising vascular 
surgery will find this book extremely helpful; 
vascular surgeons will enjoy comparing their 
own clinical experiences with those described 
in this book.
M. A. Naqvi
336 Kings Road,
Sydney, NS.
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Books Received
Anesthesia for the Uninterested. Edited by Alex­
ander A. Birch and John D. Tolmie. 187 pp. 
Illust. University Park Press, Baltimore, 1976. 
$7.50, paperbound.
Anorectal Malformations and Associated Diseases.
Progress in Pediatric Surgery. Volume 9. Exe­
cutive Editors: P. P. Rickham, W. Ch. Hecker 
and J. Prevot. 154 pp. Illust. University Park 
Press, Baltimore, 1976. $19.50.
Congenital Malformations of the Heart. Daniel 
A. Goor and C. Walton Lillehei. 430 pp. 
Illust. Grune & Stratton, Inc., New York; Long­
man Canada Limited, Toronto, 1975. $37.50. 
Lethal Diseases of the Ascending Aorta. Edited 
by Constantine E. Anagnostopoulos. 150 pp. 
Illust. University Park Press, Baltimore, 1976. 
$14.50.
Myocardial Revascularization. A Surgical Atlas.
Quentin R. Stiles, Bernard L. Tucker, George 
G. Lindesmith and Bert W. Meyer. 165 pp. 
Illust. Little, Brown and Company (Inc.), Bos­
ton, 1976. Price not stated.
Plastic and Reconstructive Surgery of the Breast. 
Edited by Robert M. Goldwyn. 565 pp. Illust. 
Little, Brown and Company (Inc.), Boston, 
1976. $48.50.
Postoperative Congenital Heart Disease. Edited by 
Ammon Rosenthal, Edmund H. Sonnenblick 
and Michael Lesch. 166 pp. Illust. Grune & 
Stratton, Inc., New York; Longman Canada 
Limited, Toronto, 1975. $16.75.
Practical Cryosurgery. Edited by H. B. Holden. 
168 pp. Illust. Pitman Medical Publishing Co. 
Ltd. Distributed by Year Book Medical Pub­
lishers, Inc., Chicago, 1975. Price not stated.
CRITIQUE OF ITEM 507 (SESAP II) 
Radioimmunoassay using gastrin labeled with 
iodine-125 is the method currently employed 
to measure serum gastrin levels. The measure­
ments in the report by McGuigan and Trudeau 
indicated that gastrin concentrations are sig­
nificantly reduced after antral resection (P less 
than 0.001). High levels of gastrin are useful 
in identifying patients with the Zollinger-Elli- 
son syndrome; levels above 500 picograms are 
diagnostic of this syndrome (normal levels are 
those below 150 pg).
Vagotomy has been shown to depress the 
responsiveness of acid-secreting parietal cells 
to both histamine and gastrin, but gastrin levels 
are of no value in investigating the possibility 
of residual vagal function after vagotomy; 
residual vagal function is determined by the 
Hollander insulin test.
Reference  —
507/1. McGuigan JE, Trudeau WL: Serum 
gastrin levels before and after vagotomy and 
pyloroplasty or vagotomy and antrectomy. N 
Engl J Med 286: 184-188, 1972
